Lipid compound and lipid nanoparticle composition

MYPI2025003904A0Undetermined Publication Date: 2024-06-28RINUAGENE BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025003904
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-25
Filing Date
2023-12-27
Publication Date
2024-06-28

AI Technical Summary

Technical Problem

Existing lipid nanoparticles have insufficient ability to accumulate in organs and tissues other than the liver, which limits the expansion of their clinical use. In addition, traditional viral vectors have problems such as immunogenicity and high cost. Non-viral vectors such as lipid nanoparticles are not stable in There are challenges in terms of safety and security.

Method used

A new lipid compound and its nanoparticle composition were developed to achieve the advantages of extrahepatic delivery and vaccine or mRNA delivery by optimizing the lipid composition and structure, improving the encapsulation rate and low toxicity of lipid nanoparticles, using Synthesis method of asymmetric tail chain cationic lipids to prepare nanoparticles with high encapsulation efficiency and low toxicity.

Benefits of technology

It achieves efficient encapsulation and delivery of therapeutic/preventive agents, improves targeting and safety, and expands the application prospects of lipid nanoparticles in the field of drug delivery, especially the delivery capability in extrahepatic organs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025003904_DRAWING_001
    Figure PI2025003904_DRAWING_001
  • Figure PI2025003904_DRAWING_002
    Figure PI2025003904_DRAWING_002
  • Figure PI2025003904_DRAWING_003
    Figure PI2025003904_DRAWING_003
Patent Text Reader

Abstract

The present application disclosed a compound of formula (I) and a salt and a stereoisomer thereof, wherein each variable is as defined in the specification. The present application also disclosed a nanoparticle composition comprising the compound or a salt or a stereoisomer thereof, and the use of the nanoparticle composition for delivering active agents.
Need to check novelty before this filing date? Find Prior Art

Description

Lipid compounds and lipid nanoparticle compositions Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to lipid compounds and lipid nanoparticle compositions. In particular, the present invention relates to a method for delivering an active agent, such as a nucleic acid, and a lipid compound and lipid nanoparticle composition for delivery. Background Art

[0002] The effective targeted delivery of bioactive substances such as small molecule drugs, proteins and nucleic acids is an ongoing medical challenge. The key to the success of gene therapy lies in whether the therapeutic drugs can be safely and effectively delivered into the target cells through the vector in vivo. Due to the relative instability of nucleic acids and the low cell permeability of such substances, the delivery of nucleic acids to cells becomes difficult. Therefore, it is necessary to develop methods and compositions to promote the delivery of therapeutic and / or preventive drugs such as nucleic acids to cells. Gene therapy vectors are divided into viral vectors and non-viral vectors. Although viral vectors are efficient delivery systems to achieve target gene transfection and therapeutic purposes, viral vectors contain immunogenic viral proteins, have limited target gene loading capacity and are expensive. As a result, lipid nanoparticles (LNPs) as non-viral vectors have received widespread attention due to their advantages such as good in vitro stability, in vivo degradation, safety and reliability, and are widely used in gene therapy research for congenital and acquired genetic defects.

[0003] Lipid-containing nanoparticles, or lipid nanoparticles, liposomes, and lipid complexes have been demonstrated to be effective delivery vehicles for bioactive substances such as small molecule drugs, proteins, and nucleic acids into and / or within cells. LNPs, small vesicles formed from one or more lipid components, can effectively encapsulate and deliver a variety of nucleic acid molecules, from DNA and RNA to chromosomes and even cells. Their defined construction scheme and ease of modification with targeting ligands facilitate large-scale production.

[0004] LNPs typically include one or more cationic lipids and / or amino (ionizable) lipids, phospholipids, structural lipids (such as cholesterol) and / or lipids containing polyethylene glycol (PEG lipids). Cationic and / or ionizable lipids include, for example, amine-containing lipids that can be easily protonated.

[0005] Lipid nanoparticle (LNP) formulations represent a revolution in nucleic acid delivery. TM It is an early example of a lipid nanoparticle product approved for clinical use. TMIt is a lipid nanoparticle-based short interfering RNA (siRNA) drug formulation for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis. The success of this LNP delivery system paves the way for the clinical development of the leading LNP-based COVID-19 mRNA vaccine.

[0006] Onpattro TM The LNP formulation consists of four main lipid components: ionizable amino lipid MC3, distearoylphosphatidylcholine (DSPC), cholesterol, and polyethylene glycol-conjugated lipid (PEG-lipid), with molar weights of 50 / 10 / 38.5 / 1.5, respectively. TM It is still considered the gold standard for comparison in LNP studies.

[0007] Although great progress has been made in the research of LNP-mediated nucleic acid delivery, it is well known that Onpattro TM The formulation accumulated primarily in liver tissue. The ability of LNPs to accumulate in organs and tissues other than the liver would greatly expand the clinical utility of these delivery systems.

[0008] Summary of the Invention

[0009] Based on this, the present application discloses a lipid compound and a lipid nanoparticle composition comprising the compound, wherein the lipid nanoparticles have the advantages of high encapsulation efficiency, low toxicity, high expression, and are suitable for vaccine or mRNA delivery and extrahepatic delivery.

[0010] Specifically, this application includes the following implementation plans (Part I):

[0011] 1. A compound of formula (I), or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof,

[0012] in,

[0013] R1 is Among them, R 1a and R 1b are independently selected from H or C1-C6 alkyl, and R2 and R3 are independently selected from H or C1-C6 alkyl, or

[0014] R1 and R2 together with the carbon atoms to which they are attached form a substituted or unsubstituted 5-7 membered nitrogen-containing heterocyclic ring, and R3 is selected from H or C1-C6 alkyl, or

[0015] R1 and R3 together with the carbon atom to which they are attached form ring A, where ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring or heterocyclic ring, and R2 is selected from H or C1-C6 alkyl;

[0016] R4, R5 and R6 are independently selected from C1-C14 alkyl;

[0017] X and Y are independently selected from O or S;

[0018] X1 and X2 are independently selected from C=O or O, and Y1 and Y2 are independently selected from C=O or O, provided that X1 and Y1, X2 and Y2 are not C=O or O at the same time;

[0019] m and n are independently selected from 0, 1 or 2, provided that m and n are not both 0;

[0020] o and p are independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0021] q is selected from 0, 1, 2, 3, 4, 5 or 6.

[0022] 2. The compound according to item 1, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein the compound of formula (I) is formula (IA),

[0023] wherein q is selected from 1, 2, 3 or 4.

[0024] 3. A compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein R4 is a C9, C10, C11 or C12 straight-chain alkyl group; and R5 and R6 are each independently selected from a C6, C7, C8 or C9 straight-chain alkyl group.

[0025] 4. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein o is 5 or 6.

[0026] 5. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein p is 7 or 8.

[0027] 6. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein X and Y are both O.

[0028] 7. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein n is 1 and m is 0; or n is 1 and m is 1; or n is 0 and m is 1;

[0029] For example, n is 1 and m is 0; for example, n is 1 and m is 1.

[0030] 8. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein the compound of formula (I) is selected from the following structural formula

[0031] 9. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein the compound of formula (I) is selected from the following structural formula

[0032] 10. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein the compound of formula (I) is selected from the following structural formula:

[0033] 11. A compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein C1-C6 alkyl is independently selected from -CH3, -CH2CH3 or -CH(CH3)2;

[0034] For example, C1-C6 alkyl is independently selected from -CH3.

[0035] 12. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein:

[0036] R 1a and R 1b independently selected from -CH3;

[0037] R2 and R3 are independently selected from H;

[0038] R4 is a C10, C11 or C12 straight chain alkyl group;

[0039] R5 and R6 are the same and are selected from C6, C7 and C8 straight chain alkyl groups;

[0040] X and Y are independently selected from O;

[0041] X1 and X2 are independently selected from C=O or O, and Y1 and Y2 are independently selected from C=O or O, provided that X1 and Y1 are not C=O or O at the same time, and X2 and Y2 are not C=O or O at the same time;

[0042] m is 0, and n is 1;

[0043] o is 5 or 6;

[0044] p is 7 or 8, for example, p is 7;

[0045] q is 2, 3 or 4, for example, q is 2 or 3, for example, q is 2;

[0046] For example, p is 7 and q is 2 or 3;

[0047] For example, p is 7 and q is 2.

[0048] 13. The compound according to any one of items 1 to 12, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein X1 and X2 are both C═O, and Y1 and Y2 are both O.

[0049] 14. The compound according to any one of items 1 to 12, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein X1 is O, Y1 is C=O, and X2 is C=O, Y2 is O.

[0050] 15. A compound according to any one of items 1 to 12, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein X1 is C=O, Y1 is O, and X2 is O, Y2 is C=O; or, X1 and X2 are both O, and Y1 and Y2 are both C=O.

[0051] 16. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein R4 is a C10-C11 straight-chain alkyl group.

[0052] 17. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein R5 and R6 are both C8 straight-chain alkyl.

[0053] 18. The compound according to any one of the preceding items, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein:

[0054] o is 5, R4 is a C11 straight chain alkyl, p is 7, and R5 and R6 are both C8 straight chain alkyl or

[0055] o is 6, R4 is a C10 straight-chain alkyl group, p is 7, and R5 and R6 are both C8 straight-chain alkyl groups.

[0056] 19. The compound according to item 1, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein the compound is selected from:

[0057] 20. The compound according to item 1, or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof, wherein the compound is selected from:

[0058] 21. A method for preparing the compound according to any one of items 1 to 20, wherein compound (IA) is obtained from compound J as a starting material,

[0059] wherein Z1 is selected from hydroxyl, Z2 and Z3 are independently selected from hydroxyl or thiol, and Z4 is selected from OMs (Ms is methylsulfonyl); and

[0060] X, Y, X1, X2, Y1, Y2, R 1a 、R 1b , R2, R3, R4, R5, R6, m, n, o, p and q are as defined in any one of items 1-20;

[0061] Wherein, the compound J and compound K react in a benzene solution of 4-methylbenzenesulfonate pyridinium to generate compound L, and the benzene solvent used in the benzene solution is preferably toluene;

[0062] The compound L reacts in a halogenated alkane solution of (CH3SO2)2O to generate compound M, wherein the halogenated alkane is preferably DCM, dichloroethane or chloroform;

[0063] The compound M reacts in a polar aprotic solvent to generate compound IA, and the polar aprotic solvent is preferably THF.

[0064] 22. The preparation method according to item 21, wherein compound J is obtained from compound H and compound C as starting materials,

[0065] wherein X is selected from halogen; and

[0066] X1, X2, R4, R5, R6, o and p are as defined in any one of items 1 to 20;

[0067] Wherein, the compound H and compound C react in the presence of carbonate, NBu4I and a polar aprotic solvent to generate compound I, wherein the carbonate is preferably Cs2CO3 or K2CO3; the polar aprotic solvent is preferably DMF or DMA;

[0068] The compound I reacts at a pH of 1-5 to generate compound J. Preferably, the pH is adjusted by a hydrochloric acid solution. The reaction solvent is a halogenated alkane, preferably DCM, dichloroethane or chloroform.

[0069] 23. The preparation method according to item 22, wherein compound H is obtained by reacting compound F with compound G,

[0070] wherein X is selected from halogen;

[0071] X1, Y1, R4 and o are as defined in any one of items 1-20;

[0072] Wherein, the compound F and compound G react in the presence of carbonate, NBu4I and a polar aprotic solvent to generate compound H, wherein the carbonate is preferably Cs2CO3 or K2CO3; and the polar aprotic solvent is preferably DMF or DMA.

[0073] 24. A nanoparticle composition comprising a lipid component, wherein the lipid component comprises a compound or a salt thereof (especially a pharmaceutically acceptable salt) or a stereoisomer thereof according to any one of items 1 to 20; preferably, the nanoparticle composition is a lipid nanoparticle (LNP).

[0074] 25. The nanoparticle composition of claim 24, wherein the lipid component further comprises phospholipids, structural lipids, and / or PEG lipids;

[0075] The phospholipids are preferably selected from one or more of the following compounds:

[0076] Dilauroyl phosphatidylcholine (DLPC),

[0077] Dimyristoylphosphatidylcholine (DMPC),

[0078] Dioleoylphosphatidylcholine (DOPC),

[0079] Dipalmitoylphosphatidylcholine (DPPC),

[0080] Distearoylphosphatidylcholine (DSPC),

[0081] Dioleoylphosphatidylcholine (DUPC),

[0082] Palmitoyloleoylphosphatidylcholine (POPC),

[0083] 1,2-di-O-octadecyl-sn-glycero-3-phosphocholine (18:0Diether PC),

[0084] 1-oleoyl-2-cholesteryldimethylsuccinate-sn-glycero-3-phosphocholine (OChemsPC),

[0085] l-hexadecyl-sn-glycero-3-phosphocholine (C16Lyso PC),

[0086] 1,2-Divinyl-sn-glycero-3-phosphocholine,

[0087] 1,2-Diaryl acyl-sn-glycero-3-phosphocholine,

[0088] 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine (DOPE),

[0089] 1,2-Dihydroxytin-sn-glycerol-3-phosphoethanolamine (ME 16.0PE),

[0090] 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine,

[0091] 1,2-Divinyl alcohol-sn-glycero-3-phosphoethanolamine,

[0092] 1,2-Divinyl-sn-glycero-3-phosphoethanolamine,

[0093] 1,2-Diaryl-sn-glycero-3-phosphoethanolamine,

[0094] 1,2-dithiohexaenoic acid-sn-glycero-3-phosphoethanolamine,

[0095] 1,2-diol-sn-glycero-3-phosphate-(1-glycerol) sodium salt (DOPG) or sphingomyelin,

[0096] For example, the phospholipid is DOPE or DSPC;

[0097] The structural lipid is preferably selected from one or more of cholesterol, coprostanol, sitosterol, ergosterol, and stigmasterol; for example, the structural lipid is cholesterol; and / or

[0098] The PEG lipid is preferably selected from one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, or PEG-modified dialkylglycerol.

[0099] 26. The nanoparticle composition of any one of items 24-25, wherein the lipid component further comprises cationic and / or ionizable lipids.

[0100] 27. The nanoparticle composition of any one of items 24-26, further comprising a therapeutic and / or prophylactic agent selected from a vaccine or a compound capable of eliciting an immune response, and / or a nucleic acid,

[0101] Preferably, the nucleic acid is RNA, and the RNA is selected from one or more of siRNA, aiRNA, miRNA, dsRNA, shRNA or mRNA.

[0102] For example, the therapeutic and / or prophylactic agent is mRNA.

[0103] 28. The nanoparticle composition of any one of items 24-27, wherein:

[0104] The encapsulation efficiency of the therapeutic agent and / or preventive agent is ≥50%; or ≥80%; or ≥90%; and / or

[0105] The average particle size of the nanoparticle composition is 50 nm to 110 nm; and / or

[0106] The dispersibility index of the nanoparticle composition is 0.04-0.20.

[0107] 29. Use of a compound according to any one of items 1 to 20, or a salt thereof (especially a pharmaceutically acceptable salt), or a stereoisomer thereof, in the preparation of a lipid nanoparticle composition.

[0108] 30. A pharmaceutical composition comprising the nanoparticle composition of any one of items 24-28 and a pharmaceutically acceptable excipient.

[0109] 31. A method for delivering a therapeutic and / or prophylactic agent to a mammalian cell, the method comprising administering to a subject the nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30, wherein the administration comprises contacting the cell with the nanoparticle composition or the pharmaceutical composition to deliver the therapeutic and / or prophylactic agent to the cell; for example, the mammalian cell is in a mammal; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0110] 32. A method for producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30 to deliver a therapeutic and / or prophylactic agent to the cell, wherein the therapeutic and / or prophylactic agent is mRNA, which encodes the polypeptide of interest, such that the mRNA can be translated in the cell to produce the polypeptide of interest; for example, the mammalian cell is in a mammal; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0111] 33. A method for treating or preventing a disease or condition in a mammal, such as a human, comprising administering to the mammal a therapeutically or prophylactically effective amount of the nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30; for example, the disease or condition is characterized by dysfunction or abnormality in protein or polypeptide activity; for example, the disease or condition is selected from infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular diseases, renal vascular diseases or metabolic diseases; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally or by inhalation.

[0112] 34. A method for specifically delivering a therapeutic and / or prophylactic agent to an organ of a mammal, the method comprising administering to the mammal the nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30, wherein the administration comprises contacting the mammalian organ with the nanoparticle composition or pharmaceutical composition, thereby delivering the therapeutic and / or prophylactic agent to the organ; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation; for example, the mammal is pretreated 24 hours or less before the contacting or administering step; for example, the mammal is pretreated about one hour before the contacting or administering step.

[0113] 35. A method of delivering a therapeutic and / or prophylactic agent to a patient, the method comprising administering the nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30 to a patient in need thereof.

[0114] 36. A method for introducing a nucleic acid into a cell, the method comprising contacting the cell with the nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30.

[0115] 37. The nanoparticle composition of any one of items 24 to 28 or the pharmaceutical composition of item 30 for use as a medicament.

[0116] 38. The nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30, for use in delivering a therapeutic and / or prophylactic agent to a mammalian cell; for example, the mammalian cell is in a mammal; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0117] 39. The nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30, for producing a polypeptide of interest in a mammalian cell, wherein the drug comprises a therapeutic and / or prophylactic agent, the therapeutic and / or prophylactic agent being an mRNA encoding the polypeptide of interest, such that the mRNA can be translated in the cell to produce the polypeptide of interest; for example, the mammalian cell is in a mammal; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0118] 40. The nanoparticle composition of any one of items 24 to 28 or the pharmaceutical composition of item 30, for use in treating or preventing a disease or condition in a mammal, such as a human.

[0119] 41. The nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30, for use in treating or preventing a disease or condition in a mammal, such as a human, characterized by dysfunction or abnormality in protein or polypeptide activity; for example, the disease or condition is selected from an infectious disease, cancer and proliferative disease, a genetic disease, an autoimmune disease, diabetes, a neurodegenerative disease, a cardiovascular disease, a renal vascular disease, or a metabolic disease; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0120] 42. The nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30, for use in the specific delivery of a therapeutic and / or prophylactic agent to an organ of a mammal; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0121] 43. The nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30, for use in the specific delivery of a therapeutic and / or prophylactic agent to an organ of a mammal; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation, wherein the mammal is pretreated 24 hours or less prior to the contacting or administration step; for example, pretreated about one hour prior to the contacting or administration step.

[0122] 44. The nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30, for use in delivering a therapeutic and / or prophylactic agent to a patient.

[0123] 45. The nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30, for use in introducing a nucleic acid into a cell.

[0124] 46. ​​Use of the nanoparticle composition of any one of items 24 to 28 or the pharmaceutical composition of item 30 in the preparation of a medicament for delivering a therapeutic and / or prophylactic agent to a mammalian cell; for example, the mammalian cell is in a mammal; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0125] 47. Use of the nanoparticle composition of any one of items 24 to 28 or the pharmaceutical composition of item 30 in the preparation of a drug for producing a target polypeptide in a mammalian cell, wherein the drug comprises a therapeutic agent and / or a prophylactic agent, and the therapeutic agent and / or prophylactic agent is an mRNA, which encodes the target polypeptide, such that the mRNA can be translated in the cell to produce the target polypeptide; for example, the mammalian cell is in a mammal; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally or by inhalation.

[0126] 48. Use of the nanoparticle composition of any one of items 24 to 28 or the pharmaceutical composition of item 30 in the preparation of a medicament for treating or preventing a disease or condition in a mammal, such as a human.

[0127] 49. Use of the nanoparticle composition of any one of items 24 to 28 or the pharmaceutical composition of item 30 in the preparation of a medicament for treating or preventing a disease or condition in a mammal, such as a human, characterized by dysfunction or abnormality in protein or polypeptide activity; for example, the disease or condition is selected from infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular diseases, renal vascular diseases or metabolic diseases; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally or by inhalation.

[0128] 50. Use of the nanoparticle composition of any one of items 24 to 28 or the pharmaceutical composition of item 30 in the preparation of a medicament for specifically delivering a therapeutic agent and / or a prophylactic agent to an organ of a mammal; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0129] 51. Use of the nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30 in the preparation of a medicament for specifically delivering a therapeutic and / or prophylactic agent to an organ of a mammal; for example, the mammal is a human; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation, wherein the mammal is pretreated 24 hours or less before the contacting or administration step; for example, the mammal is pretreated about one hour before the contacting or administration step.

[0130] 52. Use of the nanoparticle composition of any one of items 24 to 28 or the pharmaceutical composition of item 30 in the preparation of a medicament for delivering a therapeutic and / or prophylactic agent to a patient.

[0131] 53. Use of the nanoparticle composition of any one of items 24 to 28 or the pharmaceutical composition of item 30 in the preparation of a product for introducing a nucleic acid into a cell.

[0132] 54. The use of the nanoparticle composition of any one of items 24-28 or the pharmaceutical composition of item 30 for treating or preventing a disease or condition in a mammal, such as a human; for example, the disease or condition is characterized by dysfunction or abnormality of protein or polypeptide activity; for example, the disease or condition is selected from infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular diseases, renal vascular diseases or metabolic diseases; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally or by inhalation.

[0133] This application also includes the following implementation plans (Part II):

[0134] 1. A compound of formula (I), or a salt thereof or an isomer thereof,

[0135] Among them, R1 is Among them, R 1a 、R 1b are independently selected from H, C1-C6 alkyl, R2, R3 are independently selected from H or C1-C6 alkyl or

[0136] R1, R2 and the carbon atom to which they are attached together form a substituted or unsubstituted 5-7 membered nitrogen-containing heterocyclic ring, R3 is selected from H or C1-C6 alkyl or

[0137] R1, R3 and the carbon atom to which they are attached together form ring A, where ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring or heterocyclic ring, and R2 is selected from H or C1-C6 alkyl;

[0138] R4, R5, and R6 are independently selected from C1-C14 alkyl groups;

[0139] X and Y are independently selected from O or S;

[0140] X1 and X2 are independently selected from C=O or O, and Y1 and Y2 are independently selected from C=O or O, provided that X1 and Y1, X2 and Y2 are not C=O or O at the same time;

[0141] m and n are independently selected from 0, 1, and 2, provided that m and n are not 0 at the same time;

[0142] o and p are independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0143] q is selected from 0, 1, 2, 3, 4, 5, 6.

[0144] 2. The compound according to item 1, wherein the compound of formula (I) is formula (IA),

[0145] Wherein, q is selected from 0, 1, 2, 3, 4.

[0146] 3. The compound according to item 1, wherein the compound of formula (I) is formula (IB),

[0147] wherein R7 is selected from H or C1-C6 alkyl;

[0148] r is selected from 0, 1, 2, 3.

[0149] 4. The compound according to item 1, wherein the compound of formula (I) is of formula (IC) or (ID),

[0150] Wherein, Ring A is substituted by one or more R8, wherein R8 is Among them, R 8a 、R 8b Independently selected from H or C1-C6 alkyl, s is selected from 0, 1, 2, 3, 4, 5, 6.

[0151] 5. The compound according to item 4, wherein the ring A is selected from

[0152] 6. The compound according to any one of items 1 to 5, wherein R4 is C10-C11 alkyl.

[0153] 7. The compound according to item 6, wherein R4 is a C10-C11 linear alkyl group.

[0154] 8. The compound according to any one of items 1 to 7, wherein R5 and R6 are C8 alkyl.

[0155] 9. The compound according to item 8, wherein R5 and R6 are C8 linear alkyl groups.

[0156] 10. The compound according to any one of items 1 to 9, wherein o is 5 or 6.

[0157] 11. The compound according to any one of items 1 to 10, wherein p is 7 or 8.

[0158] 12. The compound according to any one of items 1 to 11, wherein

[0159] o is 5, R4 is a C11 straight chain alkyl, p is 7 and R5 and R6 are C8 straight chain alkyl or

[0160] o is 6, R4 is a C10 linear alkyl group, p is 7, and R5 and R6 are C8 linear alkyl groups.

[0161] 13. The compound according to any one of items 1 to 12, wherein X1 and X2 are C═O, and Y1 and Y2 are O.

[0162] 14. The compound according to any one of items 1 to 12, wherein X1 is O, Y1 is C═O, X2 is C═O, and Y2 is O.

[0163] 15. The compound according to any one of items 1 to 12, wherein X1 is C=O, Y1 is O, and X2 is O, and Y2 is C=O.

[0164] 16. The compound according to any one of items 1 to 12, wherein X1 and X2 are O, and Y1 and Y2 are C═O.

[0165] 17. The compound according to any one of items 1 to 16, wherein X and Y are both O.

[0166] 18. The compound according to any one of items 1 to 16, wherein n is 0 and m is 1, or n is 1 and m is 0, or n is 1 and m is 1.

[0167] 19. A compound according to any one of items 1 to 18, wherein the C1-C6 alkyl group is selected from -CH3, -CH2CH3 or -CH(CH3)2.

[0168] 20. The compound according to item 1, wherein the compound of formula (I) is selected from

[0169] 21. A method for preparing the compound according to any one of items 1 to 20, wherein compound (IA) is obtained from compound J as a starting material,

[0170] wherein Z1 is selected from hydroxyl, Z2 and Z3 are independently selected from hydroxyl or thiol, and Z4 is selected from OMs;

[0171] X and Y are independently selected from O or S;

[0172] X1 and X2 are independently selected from C=O or O, and Y1 and Y2 are independently selected from C=O or O, provided that X1 and Y1, X2 and Y2 are not C=O or O at the same time;

[0173] R 1a 、R 1b Independently selected from H or C1-C6 alkyl;

[0174] R2, R3 are independently selected from H or C1-C6 alkyl;

[0175] R4, R5, and R6 are independently selected from C1-C14 alkyl groups;

[0176] m and n are independently selected from 0, 1, and 2, provided that m and n are not 0 at the same time;

[0177] o and p are independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0178] q is selected from 0, 1, 2, 3, 4, 5, 6;

[0179] Wherein, the compound J and compound K react in a benzene solution of Tso-Py to generate compound L, and the benzene solvent is preferably toluene;

[0180] The compound L reacts in a halogenated alkane solution of (CH3SO2)2O to generate compound M, wherein the halogenated alkane is preferably DCM, dichloroethane or chloroform;

[0181] The compound M reacts in a polar aprotic solvent to generate compound IA, and the polar aprotic solvent is preferably THF.

[0182] 22. The preparation method according to item 21, wherein compound J is obtained from compound H and compound C as starting materials,

[0183] wherein X1 and X2 are independently selected from C=O or O, and Y1 and Y2 are independently selected from C=O or O, provided that X1 and Y1, X2 and Y2 are not C=O or O at the same time;

[0184] X is selected from halogen;

[0185] R4, R5, and R6 are independently selected from C1-C14 alkyl groups;

[0186] o and p are independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0187] Wherein, the compound H and compound C react in the presence of carbonate, NBu4I and a polar aprotic solvent to generate compound I, wherein the carbonate is preferably Cs2CO3 or K2CO3; the polar aprotic solvent is preferably DMF or DMA;

[0188] The compound I reacts at a pH of 1-5 to generate compound J. Preferably, the pH is adjusted by a hydrochloric acid solution. The reaction solvent is a halogenated alkane, preferably DCM, dichloroethane or chloroform.

[0189] 23. The preparation method according to item 22, wherein compound H is obtained by reacting compound F with compound G,

[0190] Wherein, X1 and Y1 are independently selected from C=O or O;

[0191] X is selected from halogen;

[0192] R4 is selected from C1-C14 alkyl;

[0193] o Choose from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0194] Wherein, the compound F and compound G react in the presence of carbonate, NBu4I and a polar aprotic solvent to generate compound H, wherein the carbonate is preferably Cs2CO3 or K2CO3; and the polar aprotic solvent is preferably DMF or DMA.

[0195] 24. A nanoparticle composition comprising a lipid component comprising the compound of any one of items 1-20.

[0196] 25. The nanoparticle composition of claim 24, wherein the lipid component further comprises a phospholipid.

[0197] 26. The nanoparticle composition according to claim 25, wherein the phospholipid is selected from one or more of the following compounds:

[0198] Dilauroyl phosphatidylcholine (DLPC),

[0199] Dimyristoylphosphatidylcholine (DMPC),

[0200] Dioleoylphosphatidylcholine (DOPC),

[0201] Dipalmitoylphosphatidylcholine (DPPC),

[0202] Distearoylphosphatidylcholine (DSPC),

[0203] Dioleoylphosphatidylcholine (DUPC),

[0204] Palmitoyloleoylphosphatidylcholine (POPC),

[0205] 1,2-di-O-octadecyl-sn-glycero-3-phosphocholine (18:0Diether PC),

[0206] 1-oleoyl-2-cholesteryldimethylsuccinate-sn-glycero-3-phosphocholine (OChemsPC),

[0207] l-hexadecyl-sn-glycero-3-phosphocholine (C16Lyso PC),

[0208] 1,2-Divinyl-sn-glycero-3-phosphocholine,

[0209] 1,2-Diaryl acyl-sn-glycero-3-phosphocholine,

[0210] 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine (DOPE),

[0211] 1,2-Dihydroxytin-sn-glycerol-3-phosphoethanolamine (ME 16.0PE),

[0212] 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine,

[0213] 1,2-Divinyl alcohol-sn-glycero-3-phosphoethanolamine,

[0214] 1,2-Divinyl-sn-glycero-3-phosphoethanolamine,

[0215] 1,2-Diaryl-sn-glycero-3-phosphoethanolamine,

[0216] 1,2-dithiohexaenoic acid-sn-glycero-3-phosphoethanolamine,

[0217] 1,2-Diol-sn-glycero-3-phosphate-(1-glycerol) sodium salt (DOPG) or sphingomyelin.

[0218] 27. The nanoparticle composition of claim 25, wherein the phospholipid is DOPE.

[0219] 28. The nanoparticle composition of claim 25, wherein the phospholipid is DSPC.

[0220] 29. The nanoparticle composition of any one of items 24 to 28, wherein the lipid component further comprises a structural lipid.

[0221] 30. The nanoparticle composition of claim 29, wherein the structural lipid is selected from one or more of cholesterol, coprostanol, sitosterol, ergosterol, and stigmasterol.

[0222] 31. The nanoparticle composition of any one of claim 29, wherein the structural lipid is cholesterol.

[0223] 32. The nanoparticle composition of any one of items 24 to 31, wherein the lipid component further comprises a PEG lipid.

[0224] 33. A nanoparticle composition according to any one of claim 32, wherein the PEG lipid is selected from one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol or PEG-modified dialkylglycerol.

[0225] 34. The nanoparticle composition of any one of items 24 to 33, wherein the lipid component further comprises cationic and / or ionizable lipids.

[0226] 35. The nanoparticle composition according to any one of items 24 to 34, further comprising a therapeutic and / or prophylactic agent selected from a vaccine or a compound capable of eliciting an immune response, a nucleic acid,

[0227] Preferably, the nucleic acid is RNA, and the RNA is selected from one or more of siRNA, aiRNA, miRNA, dsRNA, shRNA or mRNA.

[0228] 36. The nanoparticle composition of any one of items 24 to 35, wherein the encapsulation efficiency of the therapeutic and / or prophylactic agent is ≥50%; or ≥80%; or ≥90%.

[0229] 37. The nanoparticle composition of any one of items 24 to 36, wherein the nanoparticle composition has an average particle size of 50 nm to 110 nm.

[0230] 38. The nanoparticle composition of any one of items 24 to 36, wherein the nanoparticle composition has a dispersibility index of 0.04-0.20.

[0231] 39. Use of a compound according to any one of items 1 to 20 in the preparation of a lipid nanoparticle composition.

[0232] 40. A pharmaceutical composition comprising the nanoparticle composition of any one of items 24 to 38 and a pharmaceutically acceptable carrier.

[0233] 41. A method for delivering a therapeutic and / or prophylactic agent to a mammalian cell, the method comprising administering to a subject the nanoparticle composition of any one of items 24 to 38 or the pharmaceutical composition of item 40, wherein the administration comprises contacting the cell with the nanoparticle composition or the pharmaceutical composition to deliver the therapeutic and / or prophylactic agent to the cell.

[0234] 42. The method of claim 41 , wherein the mammalian cell is in a mammal.

[0235] 43. The method of item 41 or 42, wherein the mammal is a human.

[0236] 44. The method of any one of items 41 to 43, wherein the nanoparticle composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0237] 45. A method for producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the nanoparticle composition of any one of items 24 to 38 or the pharmaceutical composition of item 40 to deliver a therapeutic and / or prophylactic agent to the cell, wherein the therapeutic and / or prophylactic agent is mRNA encoding the polypeptide of interest, whereby the mRNA can be translated in the cell to produce the polypeptide of interest.

[0238] 46. ​​The method of claim 45, wherein the mammalian cell is in a mammal.

[0239] 47. The method of any one of items 45 or 46, wherein the mammal is a human.

[0240] 48. The method of any one of items 45 to 47, wherein the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0241] 49. A method of treating a disease or condition in a mammal, the method comprising administering to the mammal a therapeutically effective amount of the nanoparticle composition of any one of items 24 to 38 or the pharmaceutical composition of item 40.

[0242] 50. A method according to claim 49, wherein the disease or condition is characterized by dysfunctional or aberrant protein or polypeptide activity.

[0243] 51. The method of claim 49 or 50, wherein the disease or condition is selected from an infectious disease, cancer and proliferative disease, a genetic disease, an autoimmune disease, diabetes, a neurodegenerative disease, a cardiovascular disease, a renal vascular disease, or a metabolic disease.

[0244] 52. The method according to any one of items 49 to 51, wherein the mammal is a human.

[0245] 53. The method of any one of items 49 to 52, wherein the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0246] 54. A method for specifically delivering a therapeutic agent and / or a prophylactic agent to a mammalian organ, the method comprising administering to the mammal the nanoparticle composition of any one of items 24 to 38 or the pharmaceutical composition of item 40, wherein the administration comprises contacting the mammalian organ with the nanoparticle composition, thereby delivering the therapeutic agent and / or prophylactic agent to the organ.

[0247] 55. The method of claim 54, wherein the mammal is a human.

[0248] 56. The method of item 54 or 55, wherein the nanoparticle composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

[0249] 57. The method of any one of items 54 to 56, wherein the mammal is pretreated 24 hours or less prior to the contacting or administering step.

[0250] 58. The method of any one of items 54 to 57, wherein the mammal is pretreated about one hour prior to the contacting or administering step.

[0251] Effects of the Invention

[0252] The compounds of the present application can be used to prepare lipid nanoparticles. Nanoparticle compositions containing the compounds provided herein can achieve the encapsulation and delivery of therapeutic / prophylactic agents, safely deliver the therapeutic / prophylactic agents to the targeted location, achieve high expression, and exert the effects of the therapeutic / prophylactic agents.

[0253] The lipid nanoparticles prepared in this application have a small average particle size, a high encapsulation efficiency, and low toxicity, and have broad application prospects in the field of drug delivery.

[0254] This application reports for the first time a method for synthesizing asymmetric cationic lipid tails containing acetal structures. First, two different bromine-substituted tail compounds are synthesized. Subsequently, they undergo nucleophilic substitution reactions with tosyl isocyanide under different alkaline conditions to yield tosyl isocyanide-substituted di-long-chain compounds. Finally, acid hydrolysis yields the key intermediate, a di-tail carbonyl compound. DETAILED DESCRIPTION

[0255] The following description of exemplary embodiments of the present application includes various details of the embodiments of the present application to facilitate understanding, and should be considered as merely exemplary. Therefore, those skilled in the art will recognize that various changes and modifications may be made to the embodiments described herein without departing from the scope and spirit of the present application. Similarly, for the sake of clarity and conciseness, descriptions of well-known functions and structures are omitted in the following description.

[0256] Terms and Definitions

[0257] As used herein, the term "alkyl" refers to a group containing one or more carbon atoms (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more carbon atoms), which is optionally substituted. The term "C1-C14 alkyl" refers to an optionally substituted straight or branched saturated hydrocarbon containing 1 to 14 carbon atoms. Unless otherwise specified, the alkyl groups described herein refer to both unsubstituted and substituted alkyl groups.

[0258] As used herein, the term "carbocycle" or "carbocyclyl" refers to an optionally substituted monocyclic or polycyclic ring system comprising one or more carbon atom rings. The ring can be a ring of three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen or twenty members. The term "5-7 membered ring" refers to a carbocycle comprising a monocyclic, paracyclic or spirocyclic ring having 5-7 carbon atoms. The carbocycle can include one or more carbon-carbon double or triple bonds and can be non-aromatic or aromatic (e.g., cycloalkyl or aryl). Examples of carbocycles include cyclopentyl, cyclohexyl, phenyl, naphthyl and 1,2-dihydronaphthyl.

[0259] As used herein, "cycloalkyl" refers to a non-aromatic carbocyclic ring and may or may not include any double or triple bonds. Unless otherwise indicated, the carbocyclic rings described herein refer to both unsubstituted and substituted carbocyclic groups, i.e., optionally substituted carbocyclic rings.

[0260] As used herein, the term "heterocycle" or "heterocyclyl" refers to an optionally substituted monocyclic or polycyclic ring system comprising one or more rings, wherein at least one ring comprises at least one heteroatom, such as one, two, three, four, or five heteroatoms, which heteroatoms can be, for example, nitrogen, oxygen, or sulfur atoms. The ring can be three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen member rings. The heterocycle can include one or more double or triple bonds and can be non-aromatic or aromatic (e.g., heterocycloalkyl or heteroaryl). Examples of heterocycles include imidazolyl, imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl, pyrazolidinyl, pyrazolyl, isoxazolinyl, isoxazolyl, isothiazolidinyl, isothiazolyl, morpholinyl, pyrrolyl, pyrrolyl, pyrrolyl, pyrrolyl, pyrrolyl, furyl, thienyl, pyrrolyl, pyrrolyl, pyrrolyl, furyl, thienyl, phenyl.

[0261] As used herein, the term "heterocycloalkyl" refers to a non-aromatic heterocycle and may or may not include any double or triple bonds. Unless otherwise specified, the heterocycles described herein refer to both unsubstituted and substituted heterocyclic groups, i.e., optionally substituted heterocycles.

[0262] As used herein, "aryl" includes optionally substituted carbocyclic groups of one or more aromatic rings. Examples of aryl groups include phenyl and naphthyl.

[0263] As used herein, "heteroaryl" refers to an optionally substituted heterocyclic group comprising one or more aromatic rings. Examples of heteroaryl groups include pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, and thiazolyl. Both aryl and heteroaryl groups may be optionally substituted. Unless otherwise indicated, aryl or heteroaryl groups as described herein refer to both unsubstituted and substituted groups, i.e., optionally substituted aryl or heteroaryl groups.

[0264] Unless otherwise indicated, the alkyl group may be optionally substituted. The optional substituents may be selected from, but are not limited to, a halogen atom (e.g., chloro, bromo, fluoro, or iodo), a carboxylic acid (e.g., -C(O)OH), an alcohol (e.g., a hydroxyl group, -OH), an ester (e.g., -C(O)OR or -OC(O)R), an aldehyde (e.g., -C(O)H), a carbonyl (e.g., -C(O)R, or represented by C=O), an acyl halide (e.g., -C(O)X, wherein X is a halide selected from bromide, fluoride, chloride, and iodide), a carbonate (e.g., -OC(O)OR), an alkoxy group (e.g., -OR), an acetal, a phosphate, a thiol (e.g., -SH), a sulfoxide (e.g., -S(O)R), a sulfite (e.g., -S(O)R), a thiophene ...

[0015] In some embodiments, the substituents are alkyl, alkyl, alkylene ... 1-6 The alkyl group can be further substituted with 1, 2, 3, 4, 5, or 6 substituents as described herein.

[0265] As used herein, the term "compound" is intended to include all isomers and isotopes of the described structure. "Isotopes" refer to atoms having the same atomic number but differing in mass due to the number of neutrons in their nuclei. For example, isotopes of hydrogen include tritium and deuterium. In addition, the compounds, salts, or complexes of the present application can be prepared by conventional methods by combining with solvents or water molecules to form sols and hydrates.

[0266] As used herein, the term "contacting" refers to establishing a physical connection between two or more entities. For example, contacting a mammalian cell with a nanoparticle composition means that the mammalian cell and the nanoparticle share a physical connection. Methods for contacting cells with external entities in vivo and in vitro are well known in the field of biology. For example, a nanoparticle composition can be contacted with a mammalian cell placed in a mammal by a variety of routes of administration (e.g., intravenous, intramuscular, intradermal, and subcutaneous), and can involve a variety of amounts of the nanoparticle composition. In addition, the nanoparticle composition can contact more than one mammalian cell.

[0267] As used herein, the term "delivery" refers to providing an entity to a destination. For example, delivering a therapeutic and / or prophylactic agent to a subject can include administering a nanoparticle composition comprising a therapeutic and / or prophylactic agent to the subject (e.g., by intravenous, intramuscular, intradermal, or subcutaneous routes). Administering a nanoparticle composition to a mammal or mammalian cell can involve contacting one or more cells with the nanoparticle composition.

[0268] As used herein, term " enhanced delivery " refers to that by nanoparticle more (for example, at least 1.5 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times) therapeutic and / or preventive drug is delivered to target target tissue (for example, mammal liver) and control nanoparticle is delivered to target tissue (for example MC3, KC2 or DLinDMA) and / or the level of preventive drug is compared.Can be by the amount of protein produced in tissue and the weight of described tissue compared, by the therapeutic and / or preventive amount and the weight of tissue in tissue, by the protein amount produced in tissue and the amount of total protein in tissue compared, or by the amount of treatment and / or preventive agent in tissue and the total treatment and / or preventive agent in described tissue compared.Should be understood that nanoparticle does not need to determine in treated experimenter to the enhanced delivery of target tissue, but can determine in such as animal model (for example, rat model) surrogate. In some embodiments, the nanoparticle compositions comprising a compound of Formula (I), (IA), (IB), (IC), (ID) have substantially the same level of delivery enhancement regardless of the route of administration.

[0269] As used herein, the term "specific delivery" or "specific transport" refers to the delivery of more (e.g., at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold) of a therapeutic and / or prophylactic drug to a target tissue of interest (e.g., liver, spleen, stomach, intestines in mammals) by nanoparticles as compared to non-target tissues. The level of delivery of nanoparticles to a specific tissue can be measured by comparing the weight of protein produced in the tissue with the weight of the tissue, comparing the therapeutic and / or prophylactic amount in the tissue with the weight of the tissue, comparing the weight of protein produced in the tissue with the total protein weight in the tissue, or comparing the therapeutic and / or prophylactic amount in the tissue with the total therapeutic and / or prophylactic amount in the tissue.

[0270] As used herein, "encapsulation efficiency" refers to the amount of therapeutic and / or prophylactic agent that becomes part of a nanoparticle composition, relative to the total amount of therapeutic and / or prophylactic agent used to prepare the nanoparticle composition. For example, if 97 mg of the therapeutic and / or prophylactic agent is encapsulated in the nanoparticle composition out of a total of 100 mg of therapeutic and / or prophylactic agent initially provided to the composition, the encapsulation efficiency can be 97%. As used herein, "encapsulation" can refer to complete, substantial, or partial encapsulation, enclosure, surrounding, or encapsulation.

[0271] As used herein, "expression" of a nucleic acid sequence refers to the translation of mRNA into a polypeptide or protein and / or post-translational modification of the polypeptide or protein.

[0272] As used herein, the term "in vitro" refers to events that occur in an artificial environment, such as in a test tube or reaction vessel, in a cell culture, in a petri dish, etc., rather than in an organism (e.g., an animal, plant, or microorganism).

[0273] As used herein, the term "in vivo" refers to events that occur within an organism (eg, an animal, plant, or microorganism, or a cell or tissue thereof).

[0274] As used herein, the term "ex vivo" refers to an event that occurs outside an organism (e.g., an animal, plant, or microorganism, or a cell or tissue thereof). An ex vivo event can occur in an environment that is minimally altered from the natural (e.g., in vivo) environment.

[0275] As used herein, the term "isomer" refers to any geometric isomer, tautomer, zwitterion, stereoisomer, enantiomer or diastereomer of a compound. Compounds may contain one or more chiral centers and / or double bonds and, therefore, may exist as stereoisomers, such as double bond isomers (i.e., geometric E / Z isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis-trans isomers). This application encompasses any and all isomers of the compounds described herein. Enantiomeric and stereoisomeric mixtures of compounds and methods of resolving them into their component enantiomers or stereoisomers are well known.

[0276] As used herein, a "lipid component" is a component of a nanoparticle composition that comprises one or more lipids. For example, the lipid component can include one or more cationic / ionizable lipids, PEGylated lipids, structured lipids, or other lipids, such as phospholipids.

[0277] As used herein, a "linker" is a portion connecting two parts, for example, the connection between two nucleosides of a cap species. A linker can include one or more groups, including but not limited to a phosphate group (e.g., phosphate, borophosphate, thiophosphate, selenophosphate, and phosphate), an alkyl, an amide, or a glycerol. For example, two nucleosides of a cap analog can be connected at their 5' positions by a triphosphate group or by a chain comprising two phosphate moieties and a boric acid phosphate moiety.

[0278] As used herein, "administration method" may include intravenous, intramuscular, intradermal, subcutaneous or other methods of delivering the composition to the subject. Any administration method can be selected to target delivery (e.g., specific delivery) to a specific area or system of the body.

[0279] As used herein, "modified" refers to non-natural. For example, RNA can be modified RNA. That is, the RNA can include one or more non-naturally occurring nucleobases, nucleosides, nucleotides, or linkers. "Modified" substances may also be referred to herein as "engineered" substances. Such substances can be modified or engineered chemically, structurally, or functionally. For example, a modified nucleobase species can include one or more non-naturally occurring substitutions.

[0280] As used herein, a "nanoparticle composition" is a composition comprising one or more lipids. The particle size of the nanoparticle composition is typically on the order of microns or less and may include a lipid bilayer. Nanoparticle compositions include lipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), and lipid complexes. For example, the nanoparticle composition can be a liposome having a lipid bilayer with a diameter of 500 nm or less.

[0281] As used herein, "naturally occurring" means occurring in nature without human assistance.

[0282] As used herein, "patient" refers to a subject who may seek or need treatment, is in need of treatment, is currently receiving treatment, is about to receive treatment, or is being cared for by a trained professional for a particular condition.

[0283] As used herein, "PEG lipid" or "PEGylated lipid" refers to a lipid that comprises a polyethylene glycol component.

[0284] The term "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0285] As used herein, the phrase "pharmaceutically acceptable excipient" refers to any ingredient other than the compounds described herein (e.g., a vehicle capable of suspending, complexing, or dissolving the active compound) that is substantially non-toxic and non-inflammatory to the patient. Excipients may include, for example, anti-adherents, antioxidants, binders, coatings, compressive aids, disintegrants, dyes (colorants), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavorings, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, and water of hydration. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (diacid), calcium stearate, cross-linked carboxymethylcellulose, cross-linked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E (alpha-tocopherol), vitamin C, xylitol, and others disclosed herein.

[0286] In this application, for convenience, the structural formula of the compound represents certain isomers, but this application includes all isomers, such as geometric isomers, optical isomers based on asymmetric carbons, stereoisomers, tautomers, etc. It should be understood that not all isomers can have the same level of activity. In addition, the compound represented by the structural formula of the compound described in this application may have crystal polymorphism. Note that any crystal form, crystal form mixture or its anhydride or hydrate is included within the scope of this application.

[0287] The terms "crystal polymorph," "polymorph," or "crystalline form" refer to a crystal structure in which a compound (or a salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. The recrystallization solvent, crystallization rate, storage temperature, and other factors may cause one crystalline form to predominate. Crystal polymorphs of a compound can be prepared by crystallization under different conditions.

[0288] The nanoparticle compositions of the present application may also include salts of one or more compounds. The salts may be pharmaceutically acceptable salts. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds in which the parent compound is modified by converting an existing acid or base moiety into its salt form (e.g., by reacting a free base with a suitable organic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glucoheptonate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, palmitate, pectinate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, tosylate, undecanoate, valerate, and the like.

[0289] Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc., as well as non-toxic ammonium, quaternary ammonium and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc. The pharmaceutically acceptable salts of the present application include, for example, conventional non-toxic salts of the parent compound formed by non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present application can be synthesized from the parent compound containing an alkaline or acidic part by conventional chemical methods. Typically, these salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of a suitable base or acid in water or in an organic solvent or in a mixture of the two. Typically, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.

[0290] As used herein, " phospholipid " is a lipid comprising a phosphate moiety and one or more carbon chains, such as unsaturated fatty acid chains. Phospholipid can comprise one or more multiple (such as double or triple bonds) bonds (such as one or more unsaturated bonds). Specific phospholipid can promote fusion with membrane. For example, cationic phospholipid can interact with one or more negatively charged phospholipids of membrane (such as cell membrane or intracellular membrane). The fusion of phospholipid and membrane can allow one or more elements containing lipid composition to pass through the membrane, thereby allowing, for example, one or more elements to be delivered to the cell.

[0291] As used herein, the "polydispersity index" is a ratio that describes the uniformity of the particle size distribution of a system. Small values, such as less than 0.3, indicate a narrow particle size distribution.

[0292] As used herein, the term "polypeptide" or "polypeptide of interest" refers to a polymer of amino acid residues, typically linked by peptide bonds, which can be produced naturally (eg, isolated or purified) or synthetically.

[0293] As used herein, "RNA" refers to ribonucleic acid, which may be naturally occurring or non-naturally occurring. For example, the RNA may include modified and / or non-naturally occurring components, such as one or more nucleobases, nucleosides, nucleotides, or linkers. The RNA may include a cap structure, a chain-terminating nucleoside, a stem-loop, a polyA sequence, and / or a polyadenylation signal. The RNA may have a nucleotide sequence that encodes a polypeptide of interest. For example, the RNA may be a messenger RNA (mRNA). Translation of an mRNA encoding a specific polypeptide, for example, in vivo translation of the mRNA inside a mammalian cell, may produce the encoded polypeptide. The RNA may be selected from a non-limiting group including small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), double-stranded RNA (dsRNA), small hairpin RNA (shRNA), mRNA, and mixtures thereof.

[0294] As used herein, a "single unit dose" is a dose of any therapeutic agent that is administered in one dose / at one time / through a single route / at a single point of contact, ie, a single time.

[0295] As used herein, a "split dose" is a division of a single unit dose or total daily dose into two or more doses.

[0296] As used herein, the "total daily dose" is the amount given or prescribed over a 24-hour period. It may be administered in a single unit dose.

[0297] As used herein, "particle size" or "average particle size" in the context of a nanoparticle composition refers to the average diameter of the nanoparticle composition.

[0298] As used herein, the term "subject" or "patient" refers to any organism to which a composition according to the present application can be administered, e.g., for experimental, diagnostic, prophylactic and / or therapeutic purposes. Typical subjects include animals (e.g., mammals, e.g., mice, rats, rabbits, non-human primates, and humans) and / or plants.

[0299] As used herein, "target cell" refers to any one or more cells of interest. The cells can be found in vitro, in vivo, in situ, or in a tissue or organ of an organism. The organism can be an animal, preferably a mammal, more preferably a human, and most preferably a patient.

[0300] As used herein, "target tissue" refers to any one or more tissue types of interest to which therapeutic and / or prophylactic delivery will result in a desired biological and / or pharmacological effect. Examples of target tissues include specific tissues, organs, and systems or groups thereof. In specific applications, the target tissue may be the kidney, lung, spleen, vascular endothelium in the kidney (e.g., intracoronary or intrafemoral) or in a blood vessel (e.g., by intratumoral injection). "Non-target tissue" refers to any one or more tissue types to which expression of the encoded protein does not result in a desired biological and / or pharmacological effect. In specific applications, non-target tissues may include the liver and spleen.

[0301] The term "therapeutic agent" or "prophylactic agent" refers to any agent that, when administered to a subject, has a therapeutic, diagnostic, and / or prophylactic effect and / or elicits a desired biological and / or pharmacological effect. Therapeutic agents are also referred to as "active agents" or "active ingredients." Such agents include, but are not limited to, cytotoxins, radioactive ions, chemotherapeutic agents, small molecule drugs, proteins, and nucleic acids.

[0302] As used herein, the term "therapeutically effective amount" refers to an amount of an agent (e.g., a nucleic acid, a drug, a composition, a therapeutic agent, a diagnostic agent, a prophylactic agent, etc.) to be delivered that is sufficient when administered to a subject suffering from or susceptible to an infection, disease, disorder, and / or condition to treat, ameliorate the symptoms of, diagnose, prevent, and / or delay the onset of the infection, disease, disorder, and / or condition.

[0303] As used herein, "transfection" refers to the introduction of a species (e.g., RNA) into a cell. Transfection can be performed, for example, in vitro, ex vivo, or in vivo.

[0304] As used herein, the term "treat" refers to partially or completely alleviating, relieving, ameliorating, resolving, delaying the onset of, inhibiting the progression of, reducing the severity of, and / or reducing the incidence of one or more symptoms or features of a particular infection, disease, disorder, and / or condition. For example, "treating" cancer may refer to inhibiting the survival, growth, and / or spread of a tumor. Treatment may be performed on subjects who do not exhibit the disease, disorder, and / or condition and / or on subjects who only exhibit early signs of the disease, disorder, and / or condition in order to reduce the risk of developing a pathological condition associated with the disease, disorder, and / or condition.

[0305] The present application discloses a compound described in formula (I), or a salt thereof or an isomer thereof,

[0306] Wherein, X and Y are independently selected from O or S;

[0307] X1 and X2 are independently selected from C=O or O, and Y1 and Y2 are independently selected from C=O or O, provided that X1 and Y1, X2 and Y2 are not C=O or O at the same time;

[0308] R1 is Among them, R 1a 、R 1b are independently selected from H or C1-C6 alkyl, R2, R3 are independently selected from H or C1-C6 alkyl or

[0309] R1, R2 and the carbon atom to which they are attached together form a substituted or unsubstituted 5-7 membered nitrogen-containing heterocyclic ring, R3 is selected from H or C1-C6 alkyl or

[0310] R1, R3 and the carbon atom to which they are attached together form ring A, where ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring or heterocyclic ring, and R2 is selected from H or C1-C6 alkyl;

[0311] R4, R5, and R6 are independently selected from C1-C14 alkyl groups;

[0312] m and n are independently selected from 0, 1, and 2, provided that m and n are not 0 at the same time;

[0313] o and p are independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0314] q is selected from 0, 1, 2, 3, 4, 5, 6.

[0315] In a preferred embodiment, the R1 is In a specific embodiment, the compound of formula (I) is as shown in formula (IA), Among them, q is preferably selected from 0, 1, 2, 3, and 4.

[0316] More preferably, q is selected from 2 or 3.

[0317] More preferably, q is selected from 2.

[0318] In a preferred embodiment, the compound of formula (I) is formula (IA),

[0319] wherein q is selected from 2 or 3, R 1a 、R 1b is selected from -CH3, -CH2CH3 or -CH(CH3)2,

[0320] R2 is H, R3 is H,

[0321] n is 1, m is 0,

[0322] X and Y are both 0,

[0323] o is 5 or 6,

[0324] p is 7,

[0325] X1 and X2 are both C=O, Y1 and Y2 are O or X1 is O, Y1 is C=O, X2 is C=O, and Y2 is O,

[0326] R4 is a C10 straight chain alkyl group or a C11 straight chain alkyl group,

[0327] R5 and R6 are C8 straight chain alkyl groups.

[0328] More preferably, R 1a and R 1b are all selected from -CH3.

[0329] In a preferred embodiment, R1, R2 and the carbon atoms to which they are attached together form a substituted or unsubstituted 5-7 membered nitrogen-containing heterocyclic ring, and R3 is selected from H or C1-C6 alkyl. In a specific embodiment, the compound of formula (I) is as shown in formula (IB),

[0330] Wherein, R7 is selected from H or C1-C6 alkyl; r is selected from 0, 1, 2, 3.

[0331] In a preferred embodiment, R1, R3 and the carbon atoms to which they are attached together form ring A, which is a substituted or unsubstituted 5-7 membered carbocyclic ring or heterocyclic ring; R2 is selected from H or C1-C6 alkyl; In a specific embodiment, the compound of formula (I) is as shown in formula (IC),

[0332] Wherein, Ring A is substituted by one or more R8, wherein R8 is Among them, R 8a 、R 8b Independently selected from H or C1-C6 alkyl, s is selected from 0, 1, 2, 3, 4, 5, 6.

[0333] In a specific embodiment, the compound of formula (I) is as shown in formula (ID), Wherein, Ring A is substituted by one or more R8, wherein R8 is Among them, R 8a 、R 8b Independently selected from H or C1-C6 alkyl, s is selected from 0, 1, 2, 3, 4, 5, 6.

[0334] In a specific embodiment, the ring A is The compound of formula (IC) is shown as (IC-1),

[0335] The compound of formula (ID) is shown as (ID-1),

[0336] In a specific embodiment, the ring A is The compound of formula (IC) is shown as (IC-2),

[0337] The compound of formula (ID) is shown as (ID-2),

[0338] In a specific embodiment, the ring A is The compound of formula (IC) is shown as (IC-3),

[0339] The compound of formula (ID) is shown as (ID-3),

[0340] In a specific embodiment, the ring A is The compound of formula (IC) is shown as (IC-3), The compound of formula (IC) is shown as (IC-4), The compound of formula (IC) is shown as (IC-5)

[0341] The compound of formula (ID) is shown as (ID-3), The compound of formula (ID) is shown as (ID-4), The compound of formula (ID) is shown as (ID-5)

[0342] In a preferred embodiment, in the above formulas (I), (IA), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (ID), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), R4 is selected from C1-C14 alkyl, for example, R4 is selected from C2-C14 alkyl, R4 is selected from C3-C14 alkyl, R4 is selected from C4-C1 In a preferred embodiment, R4 is selected from a C5-C14 alkyl group, a C6-C14 alkyl group, a C7-C14 alkyl group, a C8-C14 alkyl group, a C9-C14 alkyl group, a C10-C14 alkyl group, a C10-C13 alkyl group, a C10-C12 alkyl group, and a C10-C11 alkyl group. For example, R4 is a C1 alkyl group, R4 is a C2 alkyl group, R4 is a C3 alkyl group, R4 is a C4 alkyl group, R4 is a C5 alkyl group, R4 is a C6 alkyl group, R4 is a C7 alkyl group, R4 is a C8 alkyl group, R4 is a C9 alkyl group, R4 is a C10 alkyl group, R4 is a C11 alkyl group, R4 is a C12 alkyl group, R4 is a C13 alkyl group, and R4 is a C14 alkyl group. In a further preferred embodiment, R4 is a C10 alkyl group, and in a further preferred embodiment, R4 is a C11 alkyl group.

[0343] In a preferred embodiment, the R4 is selected from C1-C14 straight chain alkyl, for example, R4 is selected from C2-C14 straight chain alkyl, R4 is selected from C3-C14 straight chain alkyl, R4 is selected from C4-C14 straight chain alkyl, R4 is selected from C5-C14 straight chain alkyl, R4 is selected from C6-C14 straight chain alkyl, R4 is selected from C7-C14 straight chain alkyl, R4 is selected from C8-C14 straight chain alkyl, R4 is selected from C9-C14 straight chain alkyl, R4 is selected from C10-C14 straight chain alkyl, C10-C1 R4 is a C3 straight chain alkyl, a C10-C12 straight chain alkyl, or a C10-C11 straight chain alkyl, for example, R4 is a C1 alkyl, R4 is a C2 alkyl, R4 is a C3 straight chain alkyl, R4 is a C4 straight chain alkyl, R4 is a C5 straight chain alkyl, R4 is a C6 straight chain alkyl, R4 is a C7 straight chain alkyl, R4 is a C8 straight chain alkyl, R4 is a C9 straight chain alkyl, R4 is a C10 straight chain alkyl, R4 is a C11 straight chain alkyl, R4 is a C12 straight chain alkyl, R4 is a C13 straight chain alkyl, or R4 is a C14 straight chain alkyl. In a further preferred embodiment, R4 is a C10 straight chain alkyl, and in a further preferred embodiment, R4 is a C11 straight chain alkyl.

[0344] In a specific implementation method, the compound of formula (I) is as shown in formula (IA-1),

[0345] In a specific implementation method, the compound of formula (I) is as shown in formula (IA-2),

[0346] In a specific implementation method, the compound of formula (I) is as shown in formula (IB-1),

[0347] In a specific implementation method, the compound of formula (I) is as shown in formula (IB-2),

[0348] In a specific implementation method, the compound of formula (I) is as shown in formula (IC-6),

[0349] In a specific implementation method, the compound of formula (I) is as shown in formula (IC-7),

[0350] In a specific implementation method, the compound of formula (I) is as shown in formula (ID-6),

[0351] In a specific implementation method, the compound of formula (I) is as shown in formula (ID-7),

[0352] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (ID), (ID-1), (ID-2), (ID-3), In (ID-4), (ID-5), (ID-6), and (ID-7), R5 is selected from C1-C14 alkyl, for example, R5 is selected from C2-C14 alkyl, R5 is selected from C3-C14 alkyl, R5 is selected from C4-C14 alkyl, R5 is selected from C5-C14 alkyl, R5 is selected from C6-C14 alkyl, R5 is selected from C7-C14 alkyl, R5 is selected from C8-C14 alkyl, R5 is selected from C8-C13 alkyl, R5 is selected from C8-C12 alkyl, R5 is selected from C8-C11 alkyl, R5 is selected from C8-C10 alkyl, R5 is selected from C8-C9 alkyl, for example, R5 R5 is C1 alkyl, R5 is C2 alkyl, R5 is C3 alkyl, R5 is C4 alkyl, R5 is C5 alkyl, R5 is C6 alkyl, R5 is C7 alkyl, R5 is C8 alkyl, R5 is C9 alkyl, R5 is C10 alkyl, R5 is C11 alkyl, R5 is C12 alkyl, R5 is C13 alkyl, R5 is C14 alkyl. In a preferred embodiment, R5 is C8 alkyl.

[0353] In a preferred embodiment, the R5 is selected from C1-C14 straight chain alkyl, for example, R5 is selected from C2-C14 straight chain alkyl, R5 is selected from C3-C14 straight chain alkyl, R5 is selected from C4-C14 straight chain alkyl, R5 is selected from C5-C14 straight chain alkyl, R5 is selected from C6-C14 straight chain alkyl, R5 is selected from C7-C14 straight chain alkyl, R5 is selected from C8-C14 straight chain alkyl, R5 is selected from C8-C13 straight chain alkyl, R5 is selected from C8-C12 straight chain alkyl, R5 is selected from C8-C11 straight chain alkyl, In a preferred embodiment, R5 is a C8-C10 straight-chain alkyl group, R5 is a C8-C9 straight-chain alkyl group, for example, R5 is a C1 alkyl group, R5 is a C2 alkyl group, R5 is a C3 straight-chain alkyl group, R5 is a C4 straight-chain alkyl group, R5 is a straight-chain C5 alkyl group, R5 is a C6 straight-chain alkyl group, R5 is a C7 straight-chain alkyl group, R5 is a C8 straight-chain alkyl group, R5 is a C9 straight-chain alkyl group, R5 is a C10 straight-chain alkyl group, R5 is a C11 straight-chain alkyl group, R5 is a C12 straight-chain alkyl group, R5 is a C13 straight-chain alkyl group, and R5 is a C14 straight-chain alkyl group. In a preferred embodiment, R5 is a C8 straight-chain alkyl group.

[0354] In a preferred embodiment, in the above formula (I), (IA), (IA-1), (IA-2), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (ID), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), R6 is selected from C1-C14 alkyl, for example, R6 is selected from C2-C14 alkyl R6 is selected from C3-C14 alkyl, R6 is selected from C4-C14 alkyl, R6 is selected from C5-C14 alkyl, R6 is selected from C6-C14 alkyl, R6 is selected from C7-C14 alkyl, R6 is selected from C8-C14 alkyl, R6 is selected from C8-C13 alkyl, R6 is selected from C8-C12 alkyl, R6 is selected from C8-C11 alkyl, R6 is selected from C8-C10 alkyl, R6 is selected from C8-C9 alkyl, for example, R6 is C1 alkyl, R6 is C2 alkyl, R6 is C3 alkyl, R6 is C4 alkyl, R6 is C5 alkyl, R6 is C6 alkyl, R6 is C7 alkyl, R6 is C8 alkyl, R6 is C9 alkyl, R6 is C16 alkyl, R6 is C11 alkyl, R6 is C12 alkyl, R6 is C13 alkyl, R6 is C14 alkyl. In a preferred embodiment, R6 is C8 alkyl.

[0355] In a preferred embodiment, the R6 is selected from C1-C14 straight chain alkyl, for example, R6 is selected from C2-C14 straight chain alkyl, R6 is selected from C3-C14 straight chain alkyl, R6 is selected from C4-C14 straight chain alkyl, R6 is selected from C5-C14 straight chain alkyl, R6 is selected from C6-C14 straight chain alkyl, R6 is selected from C7-C14 straight chain alkyl, R6 is selected from C8-C14 straight chain alkyl, R6 is selected from C8-C13 straight chain alkyl, R6 is selected from C8-C12 straight chain alkyl, R6 is selected from C8-C11 straight chain alkyl, In a preferred embodiment, R6 is a C8 straight chain alkyl group, R6 is a C10 straight chain alkyl group, R6 is a C8-C9 straight chain alkyl group, for example, R6 is a C1 alkyl group, R6 is a C2 alkyl group, R6 is a C3 straight chain alkyl group, R6 is a C4 straight chain alkyl group, R6 is a C5 straight chain alkyl group, R6 is a C6 straight chain alkyl group, R6 is a C7 straight chain alkyl group, R6 is a C8 straight chain alkyl group, R6 is a C9 straight chain alkyl group, R6 is a C10 straight chain alkyl group, R6 is a C11 straight chain alkyl group, R6 is a C12 straight chain alkyl group, R6 is a C13 straight chain alkyl group, and R6 is a C14 straight chain alkyl group. In a preferred embodiment, R6 is a C8 straight chain alkyl group.

[0356] In a preferred embodiment, the R5 is a C8 alkyl group, and the R6 is a C8 alkyl group.

[0357] In a preferred embodiment, the R5 is a C8 straight-chain alkyl group, and the R6 is a C8 straight-chain alkyl group.

[0358] In a specific implementation method, the compound of formula (I) is as shown in formula (IA-3),

[0359] In a specific implementation method, the compound of formula (I) is as shown in formula (IB-3),

[0360] In a specific implementation method, the compound of formula (I) is as shown in formula (IC-8),

[0361] In a specific implementation method, the compound of formula (I) is as shown in formula (ID-8),

[0362] In a preferred embodiment, o is 5:

[0363] In a specific implementation method, the compound of formula (I) is as shown in formula (IA-4),

[0364] In a specific implementation method, the compound of formula (I) is as shown in formula (IB-4),

[0365] In a specific implementation method, the compound of formula (I) is as shown in formula (IC-9),

[0366] In a specific implementation method, the compound of formula (I) is as shown in formula (ID-9),

[0367] In a preferred embodiment, o is 6:

[0368] In a specific implementation method, the compound of formula (I) is as shown in formula (IA-5),

[0369] In a specific implementation method, the compound of formula (I) is as shown in formula (IB-5),

[0370] In a specific implementation method, the compound of formula (I) is as shown in formula (IC-10),

[0371] In a specific implementation method, the compound of formula (I) is as shown in formula (ID-10),

[0372] In a preferred embodiment, p is 7:

[0373] In a specific implementation method, the compound of formula (I) is as shown in formula (IA-6),

[0374] In a specific implementation method, the compound of formula (I) is as shown in formula (IB-6),

[0375] In a specific implementation method, the compound of formula (I) is as shown in formula (IC-11),

[0376] In a specific implementation method, the compound of formula (I) is as shown in formula (ID-11),

[0377] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6), (IC) , (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID), (ID-1), ( Among ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), and (ID-11), the X1 and X2 are C=O, and the Y1 and Y2 are O.

[0378] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6), (IC), (I C-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID), (ID-1), (ID-2) , (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the X1 is O, Y1 is C=O, the X2 is C=O, and Y2 is O.

[0379] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6), (IC), (I C-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID), (ID-1), (ID-2) , (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the X1 is C=O, Y1 is O, the X2 is O, and Y2 is C=O.

[0380] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB -6), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), ( ID), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the X1, X2 is O, and Y1 and Y2 are C=O.

[0381] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6 ), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID) , (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the X and Y are both O.

[0382] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6 ), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID) , (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the n is 0 and m is 1.

[0383] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6 ), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID) , (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the n is 1 and m is 0.

[0384] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6 ), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID) , (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the n is 1 and m is 1.

[0385] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6), (IC), ( IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID), (ID-1), (ID- 2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the o is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0386] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6), (IC), ( IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID), (ID-1), (ID- 2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0387] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6), (IC), (IC-1), (IC-2), (IC-3), (IC-4 ), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID), (ID-1), (ID-2), (ID-3) , (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the q is 0, 1, 2, 3, 4, 5 or 6.

[0388] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB- 6), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID ), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the o is 5 or 6.

[0389] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB- 6), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID ), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the p is 7 or 8.

[0390] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB- 6), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID ), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the q is 2 or 3.

[0391] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (I B-6), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11) , (ID), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the R 2 For H.

[0392] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (I B-6), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11) , (ID), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the R 3 For H.

[0393] In a preferred embodiment, the above formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID), (ID-1), (ID -2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), the R 1a 、R 1b is -CH3.

[0394] In a preferred embodiment, the compound of formula (I) is

[0395] In a preferred embodiment, the compound of formula (I) is

[0396] In a preferred embodiment, the compound of formula (I) is

[0397] In a preferred embodiment, the compound of formula (I) is

[0398] In a preferred embodiment, the compound of formula (I) is

[0399] In a preferred embodiment, the compound of formula (I) is

[0400] In a preferred embodiment, the compound of formula (I) is

[0401] In a preferred embodiment, the compound of formula (I) is

[0402] In a preferred embodiment, the compound of formula (I) is

[0403] In a preferred embodiment, the compound of formula (I) is

[0404] In a preferred embodiment, the compound of formula (I) is

[0405] In a preferred embodiment, the compound of formula (I) is

[0406] In a preferred embodiment, the compound of formula (I) is

[0407] The present application also relates to optical isomers of the compounds:

[0408] The present application further provides a method for preparing compound (IA), comprising:

[0409] wherein Z1 is selected from hydroxyl, Z2 and Z3 are independently selected from hydroxyl or thiol, and Z4 is selected from OMs;

[0410] X and Y are independently selected from O or S;

[0411] X1 and X2 are independently selected from C=O or O, and Y1 and Y2 are independently selected from C=O or O, provided that X1 and Y1, X2 and Y2 are not C=O or O at the same time;

[0412] R 1a 、R1b Independently selected from H or C1-C6 alkyl;

[0413] R2, R3 are independently selected from H or C1-C6 alkyl;

[0414] R4, R5, and R6 are independently selected from C1-C14 alkyl groups;

[0415] m and n are independently selected from 0, 1, and 2, provided that m and n are not 0 at the same time;

[0416] o and p are independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0417] q is selected from 0, 1, 2, 3, 4, 5, 6;

[0418] Wherein, the compound J and compound K react in a benzene solution of 4-methylbenzenesulfonate pyridinium (Tso-Py) to generate compound L. The benzene solvent used in the benzene solution may be toluene, xylene, trimethylbenzene and tetramethylbenzene, etc. In a preferred embodiment of the present application, the benzene solvent is toluene;

[0419] The compound L reacts in a haloalkane solution of (CH3SO2)2O to generate a compound M. The haloalkane is referred to as a haloalkane or a haloalkane, which refers to an organic compound in which one or more hydrogen atoms in an alkane molecule are replaced by a halogen atom (fluorine, chlorine, bromine, iodine). The haloalkane in this application is not limited. In a preferred embodiment, the chloroalkane is preferably DCM, dichloroethane or chloroform;

[0420] The compound M reacts in a polar aprotic solvent to generate compound IA, and the polar aprotic solvent can be dimethyl sulfoxide (DMSO), acetone, acetonitrile, dimethylformamide, dimethylacetamide, hexamethylphosphoramide, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), dimethylacetamide (DMA), preferably tetrahydrofuran (THF).

[0421] In the above synthesis method, the source of compound J is not limited and can be purchased commercially or synthesized by itself. In a specific embodiment, compound J is synthesized by the following synthesis method:

[0422] wherein X1 and X2 are independently selected from C=O or O, and Y1 and Y2 are independently selected from C=O or O, provided that X1 and Y1, X2 and Y2 are not C=O or O at the same time;

[0423] X is selected from halogen;

[0424] R4, R5, and R6 are independently selected from C1-C14 alkyl groups;

[0425] o and p are independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0426] Wherein, the compound H and compound C react in the presence of carbonate, NBu4I and a polar aprotic solvent to form compound I (Ts represents p-toluenesulfonyl); in a preferred embodiment, the carbonate is an alkali metal carbonate, preferably Cs2CO3 or K2CO3;

[0427] The polar aprotic solvent can be dimethyl sulfoxide (DMSO), acetone, acetonitrile, dimethylformamide, dimethylacetamide, hexamethylphosphoramide, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), dimethylacetamide (DMA), preferably DMF or DMA;

[0428] The compound I reacts at a pH of 1-5 to generate compound J. Preferably, the pH is adjusted by a hydrochloric acid solution, the concentration of the hydrochloric acid is preferably 12 M, and the reaction solvent is a halogenated alkane, preferably DCM, dichloroethane or chloroform.

[0429] In the above synthesis method, the source of compound H is not limited and can be purchased commercially or synthesized by itself. In a specific embodiment, compound H is synthesized by the following synthesis method:

[0430] Wherein, X1 and Y1 are independently selected from C=O or O;

[0431] X is selected from halogen;

[0432] R4 is selected from C1-C14 alkyl;

[0433] o Choose from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10;

[0434] Wherein, the compound F and compound G react in the presence of carbonate, NBu4I and a polar aprotic solvent to generate compound H; in a preferred embodiment, the carbonate is an alkali metal carbonate, preferably Cs2CO3 or K2CO3;

[0435] The polar aprotic solvent can be dimethyl sulfoxide (DMSO), acetone, acetonitrile, dimethylformamide, dimethylacetamide, hexamethylphosphoramide, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), dimethylacetamide (DMA), preferably DMF or DMA.

[0436] The present application further provides nanoparticle compositions comprising a lipid component, wherein the lipid component comprises formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-6) provided herein. -4), (IB-5), (IB-6), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), ( IC-11), (ID), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11).

[0437] In some embodiments, the nanoparticle composition has an average particle size of 50 nm to 110 nm. For example, it can be 51 nm, 52 nm, 53 nm, 54 nm, 55 nm, 56 nm, 57 nm, 58 nm, 59 nm, 60 nm, 61 nm, 62 nm, 63 nm, 64 nm, 65 nm, 66 nm, 67 nm, 68 nm, 69 nm, 70 nm, 71 nm, 72 nm, 73 nm, 74 nm, 75 nm, 76 nm, 77 nm, 78 nm, 79 nm, 80 nm, 81nm, 82nm, 83nm, 84nm, 85nm, 86nm, 87nm, 88nm, 89nm, 90nm, 91nm, 92nm, 93nm, 94nm, 95nm, 96 nm, 97nm, 98nm, 99nm, 100nm, 101nm, 102nm, 103nm, 104nm, 105nm, 106nm, 107nm, 108nm, 109nm.

[0438] The nanoparticle composition can include, for example, lipid nanoparticles (LNPs), liposomes, lipid vesicles, and lipid complexes. In some embodiments, the nanoparticle composition is a vesicle comprising one or more lipid bilayers. In some embodiments, the nanoparticle composition comprises two or more concentric bilayers separated by an aqueous compartment. The lipid bilayers can be functionalized and / or cross-linked to each other. The lipid bilayers can include one or more ligands, proteins, or channels.

[0439] The nanoparticle compositions described herein comprise a lipid component comprising at least one compound according to Formula (I), (IA), (IIA), (IB), (IC), or (ID). For example, the lipid component of the nanoparticle composition can include one or more of Compounds 1-32. The nanoparticle compositions can also comprise a variety of other components. For example, in addition to the compound according to Formula (I), (IA), (IIA), (IB), (IC), or (ID), the lipid component of the nanoparticle composition can also include one or more other lipids.

[0440] The lipid component of the nanoparticle composition may include one or more PEG or PEG-modified lipids. Such substances may alternatively be referred to as PEGylated lipids. PEG lipids are lipids modified with polyethylene glycol. PEG lipids can be selected from the non-limiting group of PEG-modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified diacylglycerols, PEG-modified dialkylglycerols, and mixtures thereof. For example, the PEG lipid can be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or PEG-DSPE lipids.

[0441] The lipid component of the nanoparticle composition can include one or more structural lipids.Structural lipids can be selected from, but are not limited to, cholesterol, coprostanol, sitosterol, ergosterol, stigmasterol and mixtures thereof, but are not limited thereto. In some embodiments, the structural lipid is cholesterol. In some embodiments, the structural lipid includes cholesterol and a corticosteroid (e.g., prednisolone, dexamethasone, prednisone and hydrocortisone), or a combination thereof.

[0442] The lipid component of the nanoparticle composition may include one or more phospholipids. The phospholipids used in the nanoparticle composition and method may be selected from

[0443] Dilauroyl phosphatidylcholine (DLPC),

[0444] Dimyristoylphosphatidylcholine (DMPC),

[0445] Dioleoylphosphatidylcholine (DOPC),

[0446] Dipalmitoylphosphatidylcholine (DPPC),

[0447] Distearoylphosphatidylcholine (DSPC),

[0448] Dioleoylphosphatidylcholine (DUPC),

[0449] Palmitoyloleoylphosphatidylcholine (POPC),

[0450] 1,2-di-O-octadecyl-sn-glycero-3-phosphocholine (18:0Diether PC),

[0451] 1-oleoyl-2-cholesteryldimethylsuccinate-sn-glycero-3-phosphocholine (OChemsPC),

[0452] l-hexadecyl-sn-glycero-3-phosphocholine (C16Lyso PC),

[0453] 1,2-Divinyl-sn-glycero-3-phosphocholine,

[0454] 1,2-Diaryl acyl-sn-glycero-3-phosphocholine,

[0455] 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine (DOPE),

[0456] 1,2-Dihydroxytin-sn-glycerol-3-phosphoethanolamine (ME 16.0PE),

[0457] 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine,

[0458] 1,2-Divinyl alcohol-sn-glycero-3-phosphoethanolamine,

[0459] 1,2-Divinyl-sn-glycero-3-phosphoethanolamine,

[0460] 1,2-Diaryl-sn-glycero-3-phosphoethanolamine,

[0461] 1,2-dithiohexaenoic acid-sn-glycero-3-phosphoethanolamine,

[0462] 1,2-Diol-sn-glycero-3-phosphate-(1-glycerol) sodium salt (DOPG) or sphingomyelin.

[0463] In some embodiments, the nanoparticle composition comprises DSPC. In some embodiments, the nanoparticle composition comprises DOPE. In some embodiments, the nanoparticle composition comprises DSPC and DOPE.

[0464] In some embodiments, nanoparticle compositions comprising one or more lipids described herein may further comprise one or more adjuvants, such as, for example, glucopyranosyl lipid adjuvant (GLA), CpG oligodeoxynucleotides (e.g., class A or class B), poly (I:C), aluminum hydroxide, and Pam3CSK4.

[0465] The nanoparticle compositions may comprise one or more therapeutic and / or prophylactic agents.

[0466] The present application provides methods for delivering therapeutic and / or prophylactic agents to mammalian cells or organs, producing a polypeptide of interest in mammalian cells, and treating a disease or condition in a mammal in need thereof, the method comprising administering to the mammal and / or contacting the mammalian cells with a composition comprising therapeutic and / or prophylactic nanoparticles.

[0467] The therapeutic and / or prophylactic agents include biologically active substances and may alternatively be referred to as "active agents." A therapeutic and / or prophylactic agent can be a substance that, once delivered to a cell or organ, produces a desired change in a cell, organ, or other body tissue or system. Such substances can be used to treat one or more diseases, disorders, or conditions. In some embodiments, the therapeutic and / or prophylactic agent is a small molecule drug that can be used to treat a specific disease, disorder, or condition. Examples of drugs that can be used in the nanoparticle compositions include, but are not limited to, antineoplastic agents (e.g., vincristine, doxorubicin, mitoxantrone, camptothecin, cisplatin, bleomycin, cyclophosphamide, methotrexate, and streptozotocin), antitumor agents (e.g., actinomycin D, vincristine), vinblastine, cystine arabinoside, anthracyclines, alkylating agents, platinum compounds, antimetabolites, and nucleoside analogs (e.g., methotrexate, purine and pyrimidine analogs), anti-infective agents, local anesthetics (e.g., dibucaine and chlorpromazine), beta-adrenergic blocking agents (e.g., propranolol, timolol, and laxatives), and sedatives. betadalafil), antihypertensives (e.g., clonidine and hydralazine), antidepressants (e.g., imipramine, amitriptyline, and doxepin), anticonversion agents (e.g., phenytoin), antihistamines (e.g., diphenhydramine, chlorpheniramine, and promethazine), antibiotics / antibacterials (e.g., gentamicin, ciprofloxacin, and cefoxitin), antifungals (e.g., miconazole, terconazole, econazole, isoconazole, butoconazole, clotrimazole, itraconazole, nystatin, and naftifine), antiparasitics, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, antiglaucoma agents, vitamins, anesthetics, and imaging agents.

[0468] In some embodiments, the therapeutic and / or prophylactic agent is a cytotoxin, a radioactive ion, a chemotherapeutic agent, a vaccine, a compound that elicits an immune response, and / or another therapeutic and / or prophylactic agent. Cytotoxins or cytotoxic agents include any agent that may be harmful to cells. Examples include, but are not limited to, paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthraquinone, ketomethasone, 1-nortestosterone, oryzae, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, maytansinoids, e.g., maytansinol, racletin (CC-1065), and analogs or homologs thereof. Radioactive ions include, but are not limited to, iodine (e.g., iodine-125 or iodine-131), strontium-89, phosphorus, palladium, cesium, iridium, phosphate, cobalt, yttrium-90, sa-153, and. Vaccines include compounds and formulations that can provide immunity to one or more conditions associated with infectious diseases (e.g., influenza, measles, human papillomavirus (HPV), rabies, meningitis, pertussis, tetanus, plague, hepatitis, and tuberculosis), including mRNA encoding antigens and / or epitopes derived from infectious diseases. Vaccines also include compounds and formulations that direct an immune response against cancer cells and may include mRNA encoding tumor cell-derived antigens, epitopes, and / or neo-epitopes. Compounds that elicit an immune response may include vaccines, corticosteroids (e.g., dexamethasone), and other species.

[0469] Other therapeutic and / or prophylactic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarboxylase), alkylating agents (e.g., methylchlorothiazide, thiotepa-chloramphenicol, racchelomycin (CC-1065), melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamineplatin (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunorubicin) and doxorubicin), antibiotics (e.g., dacomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and antimitotic agents (e.g., vincristine, vinblastine, paclitaxel, and zeaxanthin).

[0470] In some embodiments, vaccines and / or compounds capable of eliciting an immune response are prepared by comprising a vaccine comprising Formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA-F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6) , (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), for example, a composition of one or more of compounds 1-32 is administered intramuscularly. Other therapeutic and / or preventive measures include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarboxazid), alkylating agents (e.g., methoxazole, thiopyradex, chlorambucil (CC-1065), melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin, melamidin, doxorubicin, dactinomycin), anthracyclines (AMC)), and antimitotic agents (e.g., vincristine, vinblastine, paclitaxel, and maytansine alkaloids).

[0471] In other embodiments, the therapeutic and / or prophylactic agent is a protein. Therapeutic proteins that can be used in the nanoparticle compositions described herein include, but are not limited to, gentamicin, amikacin, insulin, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), factor VIR, luteinizing hormone-releasing hormone (LHRH) analogs, interferon, heparin, hepatitis B surface antigen, typhoid vaccine, and cholera vaccine.

[0472] In some embodiments, therapeutic agents are polynucleotides or nucleic acids (e.g., ribonucleic acids or deoxyribonucleic acids). The term "polynucleotide", in its broadest sense, includes any compound and / or substance that is bound or can be bound to an oligonucleotide chain. The exemplary polynucleotides used according to the present invention include, but are not limited to, deoxyribonucleic acid (DNA), ribonucleic acid (RNA) including messenger mRNA (mRNA), its hybrids, RNAi inducers, RN-Ai reagents, siRNA, shRNA, miRNA, antisense RNA, ribozymes, catalytic DNA, RNA that induces triple helix formation, aptamers, carriers, etc. One or more. In some embodiments, therapeutic and / or preventive is RNA. The RNA that can be used for the compositions and methods described herein can be selected from, but is not limited to, short polymers, antigametocytes, antisense, ribozymes, small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), double-stranded RNA (dsRNA), small hairpin RNA (shRNA), transfer RNA (tRNA), messenger RNA (mRNA) and mixtures thereof. In certain embodiments, RNA is mRNA.

[0473] In certain embodiments, the therapeutic and / or preventive agent is mRNA. The mRNA can encode any target polypeptide, including any naturally occurring or non-naturally occurring or otherwise modified polypeptide. The polypeptide encoded by the mRNA can have any size and can have any secondary structure or activity. In some embodiments, when expressed in a cell, the polypeptide encoded by the mRNA can have a therapeutic effect.

[0474] In other embodiments, the therapeutic and / or preventive agent is siRNA. siRNA may be able to selectively knock down or lower the expression of a target gene. For example, siRNA can be selected to silence a gene associated with a specific disease, disorder or condition when administering a nanoparticle composition comprising siRNA to a subject in need thereof. siRNA can comprise a sequence complementary to the mRNA sequence encoding a gene of interest or protein. In some embodiments, siRNA can be an immunomodulatory siRNA.

[0475] In some embodiments, the therapeutic and / or preventive agent is a vector or plasmid comprising shRNA or the shRNA encoding the shRNA. After a suitable construct is delivered to the nucleus, shRNA can be produced inside the target cell. Constructs and mechanisms relevant to shRNA are well known in the art.

[0476] In addition to those described in the preceding sections, the nanoparticle compositions of the present application may further comprise one or more components. For example, the nanoparticle compositions may comprise one or more small hydrophobic molecules, such as vitamins (e.g., vitamin A or vitamin E) or sterols.

[0477] The nanoparticle composition may also include one or more permeability enhancer molecules, carbohydrates, polymers, surface modifiers or other components. The permeability enhancer molecules may be molecules described in U.S. Patent Application 2005 / 0222064. The carbohydrates may include monosaccharides (e.g., glucose) and polysaccharides (e.g., glycogen and its derivatives and analogs).

[0478] The nanoparticle composition may further comprise one or more polymers, which may be biodegradable and / or biocompatible. The polymer may be selected from, but not limited to, polyamines, polyethers, polyamides, polyesters, polyurethanes, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyleneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitrs, and polyarylates. For example, the polymer may include polycaprolactone (PCL), ethylene vinyl acetate polymer (EVA), polylactic acid (PLA), poly-L-lactic acid (PLLA), polyglycolic acid (PGA), poly(lactic acid-glycolic acid) (PLGA), poly(L-lactic acid-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-caprolactone-glycolide), poly(D,L-lactide-PEO-co-D,L-lactide), poly(D,L-lactide) lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacrylates, polyurethanes, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethylene glycol, poly-L-glutamic acid, polyhydroxy acids, polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes such as polyethylene and polypropylene; polyalkylene glycols such as poly(ethylene glycol) (PEG); polyalkylene oxides (PEO); polyalkylene terephthalates such as polyethylene terephthalate; polyvinyl alcohol (PVA); polyvinyl ethers, polyvinyl esters such as poly (vinyl acetate), polyvinyl halides such as polyvinyl chloride (PVC), polyvinyl pyrrolidone (PVP), polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocellulose, hydroxypropyl cellulose, carboxymethyl cellulose, acrylic polymers such as poly(methyl (meth))acrylate) (PMMA), polyethyl (meth)acrylate, polybutyl (meth)acrylate, polyisobutyl (meth)acrylate, polyhexyl (meth)acrylate, polyisodecyl (meth)acrylate, polylauryl (meth)acrylate Esters, poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) and copolymers and mixtures thereof, polydioxanone and its copolymers, polyhydroxyalkanoates, polypropylene fumarate, polyoxymethylene, poloxamers, polyethylenediamine, poly(orthoesters), poly(butyric acid), poly(valeric acid), poly(lactide-caprolactone), trimethylene carbonate, poly(N-acryloylmorpholine) (PAcM), poly(2-methyl-2-oxazoline (PMOX), poly(2-ethyl-2-oxazoline) (PEOZ) and polyglycerol.

[0479] The nanoparticle composition may further comprise one or more surface-altering agents, which may include, but are not limited to, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as dimethyldioctadecyl-ammonium bromide), sugars or sugar derivatives (e.g., cyclodextrins), nucleic acids, polymers (e.g., heparin, polyethylene glycol, and poloxamer), mucolytics (e.g., acetylcysteine, mugwort, bromelain, papain, scleroderma, bromcaprolactone, carboxytine, eprozinone, mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosin beta 4, dornase alfa, neltenexine, and erdosteine), and DNases (e.g., rhDNase). The surface-altering agent can be disposed within the nanoparticle and / or on the surface of the nanoparticle composition (e.g., by coating, adsorption, covalent bonding, or other methods).

[0480] The nanoparticle composition may also include one or more functionalized lipids. For example, a lipid may be functionalized with an alkynyl group that undergoes a cycloaddition reaction when exposed to an azide under appropriate reaction conditions. In particular, the lipid bilayer may be functionalized in this manner with one or more groups that facilitate membrane permeation, cell recognition, or imaging. The surface of the nanoparticle composition may also be conjugated to one or more useful antibodies. Functional groups and conjugates useful for targeted cell delivery, imaging, and membrane permeation are well known in the art.

[0481] In addition to the above components, the nanoparticle composition can include any substance useful in a pharmaceutical composition. For example, the nanoparticle composition can include one or more pharmaceutically acceptable excipients or auxiliary ingredients, such as, but not limited to, one or more solvents, dispersion media, diluents, dispersing aids, suspending agents, granulation aids, disintegrants, fillers, glidants, liquid carriers, binders, surfactants, isotonicity agents, thickeners or emulsifiers, buffers, lubricants, oils, preservatives, and other substances. Excipients such as waxes, butters, colorants, coatings, flavorings, and fragrances may also be included. Pharmaceutically acceptable excipients are well known in the art.

[0482] Examples of diluents may include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and / or combinations thereof. Granulating and dispersing agents may be selected from potato starch, corn starch, tapioca starch, sodium starch glycolate, clay, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly (vinyl-pyrrolidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water-insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate, sodium lauryl sulfate, quaternary ammonium compounds, and / or combinations thereof.

[0483] Surfactants and / or emulsifiers may include, but are not limited to, natural emulsifiers (e.g., gum arabic, agar, alginic acid, sodium alginate, cartilage, cholesterol, xanthan gum, pectin, gelatin, egg yolk, casein, lanolin, cholesterol, waxes, and lecithin), colloidal clays (e.g., bentonite [aluminum silicate] and [magnesium aluminum silicate]), long-chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol), triacetin monostearate, ethylene glycol distearate, glyceryl monostearate and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate [TW ], polyoxyethylene sorbitan Polyoxyethylene sorbitan monooleate Sorbitan monopalmitate Sorbitan monostearate Sorbitan tristearate Glyceryl monooleate, Sorbitan monooleate ), polyoxyethylene esters (such as polyoxyethylene monostearate Polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate and ), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. ), polyoxyethylene ethers (e.g. polyoxyethylene lauryl ether ), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium and / or combinations thereof.

[0484] Binders can be starches (e.g., corn starch and starch paste); gelatin; sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol); natural and synthetic gums (e.g., gum arabic, sodium alginate, Irish moss extract, panwar gum, gati gum, mucilage from isapol bean hulls, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl pyrrolidone), magnesium aluminum silicate); and larch arabinogalactan); alginate polyethylene oxide polyethylene glycol; inorganic calcium salt; silicate polymethacrylate wax water; alcohol; and combinations thereof or any other suitable binder.

[0485] The example of preservative can include but is not limited to antioxidant, chelating agent, antimicrobial preservative, antifungal preservative, alcohol preservative, acidic preservative and / or other preservative.The example of antioxidant includes but is not limited to alpha-tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium metabisulfite, sodium metabisulfite and / or sodium sulfite.The example of chelating agent includes ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid and / or trisodium edetate. Examples of antibacterial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bromophenol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chlorooxylenol, cresol, ethanol, glycerol, hexyloxybutanol, imidodiuron, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol and / or thimerosal. Examples of antifungal preservatives include, but are not limited to, butylparaben, methylparaben, ethylparaben, propylparaben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate and / or sorbic acid. Examples of alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, benzyl alcohol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate and / or phenylethyl alcohol. Examples of acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroascorbic acid, ascorbic acid, sorbic acid and / or phytic acid. Other preservatives include, but are not limited to, tocopherol, tocopheryl acetate, dehydroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Methylparaben, NEOLONE TM , KATHON TM and / or

[0486] Examples of buffering agents include, but are not limited to, citrate buffer solution, acetate buffer solution, phosphate buffer solution, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium gluconate, calcium gluconate, calcium gluconate, d-gluconic acid, calcium glycerophosphate, calcium lactate, calcium lactobionate, propionic acid, calcium levulinate, valeric acid, dicalcium phosphate, phosphoric acid, tricalcium phosphate, dibasic calcium phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixture, dipotassium phosphate, potassium dihydrogen phosphate, potassium phosphate mixture, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, disodium phosphate, sodium dihydrogen phosphate, sodium phosphate mixture, tromethamine, sulfamate buffer, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethanol, and / or combinations thereof. The lubricant may be selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, silicon dioxide, talc, malt, hydrogenated vegetable oil, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium laurate, sodium sulfate, sodium lauryl sulfate, and combinations thereof.

[0487] Examples of oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, chamomile, canola, coriander, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba oil, lavender, lavender, lemon, macadamia nut, mallow, mango seed, mink, nutmeg, olive, Orange, palm, palmitone, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, fragrance, sea buckthorn, sesame, shea butter, silicone, soy, sunflower, tea tree, thistle, tsubaki, vetiver, walnut and wheat germ oils and butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone, dimethicone, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil and / or combinations thereof.

[0488] The nanoparticle compositions described herein can include a lipid component and one or more other components, such as therapeutic and / or prophylactic agents. Nanoparticle compositions can be designed for one or more specific applications or objectives. Elements of a nanoparticle composition can be selected based on the specific application or objective and / or based on the efficacy, toxicity, cost, ease of use, availability, or other characteristics of one or more elements. Similarly, a specific formulation of a nanoparticle composition can be selected for a specific application or objective based on, for example, the efficacy and toxicity of a specific combination of elements.

[0489] The lipid component of the nanoparticle composition may include, for example, a composition according to Formula (I), (IA), (IA-1), (IA-2), (IA-3), (IA-4), (IA-5), (IA-6), (IIA), (IIA-A), (IIA-B), (IIA-C), (IIA-D), (IIA-E), (IIA- F), (IIA-G), (IIA-H), (IB), (IB-1), (IB-2), (IB-3), (IB-4), (IB-5), (IB-6), (IC), (IC-1), (IC-2), (IC-3), (IC-4), (IC-5), (IC-6), (IC-7), (IC-8), (IC-9), (IC-10), (IC-11), (ID), (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10), (ID-11), phospholipids (e.g., unsaturated lipids such as DOPE or DSPC), PEG lipids and structured lipids.

[0490] The nanoparticle composition can be designed for one or more specific applications or targets. For example, a nanoparticle composition can be designed to deliver therapeutic and / or prophylactic agents such as RNA to specific cells, tissues, organs, or systems or groups thereof in a mammal. The physicochemical properties of the nanoparticle composition can be changed to increase selectivity for specific body targets. For example, the particle size can be adjusted based on the window size of different organs. The therapeutic and / or prophylactic agent included in the nanoparticle composition can also be selected based on the desired one or more delivery targets. For example, a therapeutic and / or prophylactic agent can be selected for a specific indication, condition, disease or disorder and / or for delivery (e.g., local or specific delivery) to a specific cell, tissue, organ, or system or group thereof. In certain embodiments, a nanoparticle composition can include an mRNA encoding a polypeptide of interest that can be translated intracellularly to produce a polypeptide of interest. Such a composition can be designed to be specifically delivered to a specific organ. In some embodiments, the composition can be designed to be specifically delivered to the liver of a mammal.

[0491] The amount of the therapeutic and / or prophylactic agent in the nanoparticle composition can depend on the size, composition, desired target and / or application, or other properties of the nanoparticle composition, as well as the properties of the therapeutic and / or prophylactic agent. For example, the amount of RNA that can be used in the nanoparticle composition can depend on the size, sequence, and other characteristics of the RNA. The relative amounts of the therapeutic and / or prophylactic agent and other elements (e.g., lipids) in the nanoparticle composition can also vary.

[0492] The properties of the nanoparticle composition can depend on its components. For example, a nanoparticle composition comprising cholesterol as a structural lipid can have different properties than a nanoparticle composition comprising a different structural lipid. Similarly, the properties of a nanoparticle composition can depend on the absolute or relative amounts of its components. For example, a nanoparticle composition comprising a higher mole fraction of phospholipid can have different properties than a nanoparticle composition comprising a lower mole fraction of phospholipid. Properties can also vary depending on the method and conditions used to prepare the nanoparticle composition.

[0493] The nanoparticle compositions can be characterized by a variety of methods. For example, microscopy (e.g., transmission electron microscopy or scanning electron microscopy) can be used to examine the morphology and size distribution of the nanoparticle compositions. Dynamic light scattering or potentiometric methods (e.g., potentiometric titration) can be used to measure the zeta potential. Dynamic light scattering can also be used to determine particle size.

[0494] The average particle size of the nanoparticle composition is 50 nm to 110 nm.

[0495] The nanoparticle composition can be relatively uniform. The polydispersity index can be used to indicate the uniformity of the nanoparticle composition, for example, the particle size distribution of the nanoparticle composition. A small polydispersity index (e.g., less than 0.3) generally indicates a narrow particle size distribution. The polydispersity index of the nanoparticle composition is 0.04-0.20. For example, it can be 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, or 0.19.

[0496] The encapsulation efficiency of a therapeutic and / or prophylactic agent describes the amount of therapeutic and / or prophylactic agent that is encapsulated or otherwise associated with the nanoparticle composition after preparation relative to the initial amount provided. The higher the encapsulation efficiency, the better (e.g., close to 100%). The encapsulation efficiency can be measured, for example, by comparing the amount of therapeutic and / or prophylactic agent in a solution containing the nanoparticle composition before and after decomposition of the nanoparticle composition with one or more organic solvents or detergents. Fluorescence can be used to measure the amount of free therapeutic and / or prophylactic (e.g., RNA) in the solution. For the nanoparticle compositions described herein, the encapsulation efficiency of the therapeutic and / or prophylactic agent can be at least 50%, e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In some embodiments, the encapsulation efficiency can be at least 80%. In certain embodiments, the encapsulation efficiency can be at least 90%.

[0497] The nanoparticle compositions may optionally include one or more coatings. For example, the nanoparticle compositions may be formulated into coated capsules, films, or tablets. Capsules, films, or tablets containing the compositions described herein may have any useful size, tensile strength, hardness, or density.

[0498] The nanoparticle compositions of the present application can be formulated in whole or in part as pharmaceutical compositions. The pharmaceutical compositions may comprise one or more nanoparticle components. For example, the pharmaceutical compositions may comprise one or more nanoparticle compositions comprising one or more different therapeutic and / or prophylactic agents. The pharmaceutical compositions may further comprise one or more pharmaceutically acceptable excipients or adjuvants, such as those described herein, except where any conventional excipients or adjuvants may be incompatible with one or more components of the nanoparticle composition. If an excipient or adjuvant is incompatible with a component of the nanoparticle composition, its combination with that component may result in any undesirable biological or other deleterious effects.

[0499] In some embodiments, one or more excipients or adjuvants may comprise greater than 50% of the total mass or volume of the pharmaceutical composition comprising the nanoparticle composition. For example, one or more excipients or adjuvants may comprise 50%, 60%, 70%, 80%, 90% or more of the pharmaceutical composition as is customary. In some embodiments, the pharmaceutically acceptable excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% pure. In some embodiments, the excipient is approved for human and veterinary use.

[0500] Depending on the one or more nanoparticle compositions in the pharmaceutical compositions of the present application, the relative amounts of one or more pharmaceutically acceptable excipients and / or any other ingredients will vary, depending on the identity, size, and / or disease condition of the subject being treated, and further depending on the route of administration of the composition. For example, the pharmaceutical composition may contain 0.1% to 100% (wt / wt) of the one or more nanoparticle compositions.

[0501] The nanoparticle compositions and / or pharmaceutical compositions comprising one or more of the nanoparticle compositions can be administered to any patient or subject, including those patients or subjects who may benefit from the therapeutic effect provided by delivering a therapeutic and / or prophylactic agent to one or more specific cells, tissues, organs, or systems or groups thereof (e.g., the renal system). Although the descriptions of the nanoparticle compositions and pharmaceutical compositions comprising the nanoparticle compositions provided herein are primarily directed to compositions suitable for administration to humans, it will be understood by those skilled in the art that such compositions are generally suitable for administration to any other mammal. It is well known to modify compositions suitable for administration to various animals, and such modifications can be designed and / or performed by a skilled veterinary pharmacologist using only ordinary (if any) experimentation, including but not limited to humans, other primates, and other artificial animals, including commercially relevant mammals such as cows, pigs, dogs, sheep, cats, dogs, mice, and / or rats.

[0502] Pharmaceutical compositions comprising one or more nanoparticle compositions can be prepared by any method known or hereafter developed in the art of pharmacology. Generally, such preparation methods involve combining the active ingredient with an excipient and / or one or more other auxiliary ingredients and then, if desired or necessary, dividing, shaping, and / or packaging the product into the desired single or multi-dose units.

[0503] The pharmaceutical compositions according to the present application can be prepared, packaged, and / or sold in batches of single unit doses and / or multiple single unit doses. As used herein, a "unit dose" is a precise amount of a pharmaceutical composition containing a predetermined amount of an active ingredient (e.g., a nanoparticle composition). The amount of the active ingredient is generally equal to the dose of the active ingredient to be administered to a subject and / or a convenient portion of the dose, such as half or one-third of the dose.

[0504] Pharmaceutical compositions can be prepared in a variety of forms suitable for a variety of routes and methods of administration. For example, pharmaceutical compositions can be prepared in liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and medicaments), injectable forms, solid dosage forms (e.g., capsules, tablets, tablets, etc.) (liquids, powders, and granules), dosage forms for topical and / or transdermal administration (e.g., ointments, creams, lotions, gels, powders, solutions, sprays, inhalants, and patches), suspensions, powders, and other forms. Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and / or medicaments.

[0505] In addition to the active ingredient, the liquid dosage form can include inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oil (particularly cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and sorbitan fatty acid esters and mixtures thereof. In addition to the inert diluent, oral compositions can also include other therapeutic and / or prophylactic agents, other agents, such as wetting agents, emulsifying agents and suspending agents, sweeteners, flavorings and / or spices. In certain embodiments for parenteral administration, the composition is mixed with a solubilizing agent (e.g., alcohol, oil, modified oil, glycol, polysorbate, cyclodextrin, polymer and / or a combination thereof).

[0506] Injectable preparations, such as sterile injectable aqueous or oily suspensions, can be prepared using suitable dispersants, wetting agents and / or suspending agents according to known techniques. Sterile injectable preparations can be sterile injectable solutions, suspensions and / or emulsions in nontoxic parenteral acceptable diluents and / or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water. Sterile fixed oils are generally used as solvents or suspending media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. Fatty acids such as oleic acid can be used in the preparation of injections.

[0507] The injectable formulations can be sterilized by, for example, filtration through a bacteria-retaining filter and / or by incorporating sterilizing agents in the form of sterile solid compositions prior to dissolution or dispersion in sterile water or other sterile injectable medium.

[0508] In order to prolong the effect of the active ingredient, it is generally desired to slow down the absorption of the active ingredient from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of a crystalline or amorphous substance with poor water solubility. The absorption rate of the drug then depends on its dissolution rate, which in turn depends on the crystal size and crystalline form. Alternatively, delayed absorption of the drug form for parenteral administration can be achieved by dissolving or suspending the drug in an oil carrier. The injectable drug depot form is made by forming a microcapsule matrix of the drug in a biodegradable polymer (such as polylactic acid-polyethylene glycol). Depending on the ratio of the drug to the polymer and the properties of the specific polymer used, the drug release rate can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Reserve injection preparations are prepared by embedding the drug in liposomes or microemulsions compatible with body tissues.

[0509] Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing the composition with a suitable non-irritating excipient such as cocoa butter, polyethylene glycol or a suppository wax which is solid at ambient temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity to release the active ingredient.

[0510] Solid dosage forms for oral administration include capsules, tablets, pills, films, powders and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert pharmaceutically acceptable excipient such as sodium citrate or dicalcium phosphate and / or fillers or extenders (e.g., starch, lactose, sucrose, glucose, mannitol and silicic acid), binders (e.g., carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic), humectants (e.g., glycerol), disintegrants (e.g., agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate), solubilizers (e.g., paraffin), absorption accelerators (e.g., quaternary ammonium compounds), wetting agents (e.g., cetyl alcohol and glyceryl monostearate), absorbents (e.g., kaolin and bentonite, silicates) and lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate) and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.

[0511] Solid compositions of similar types can be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or lactose and high molecular weight polyethylene glycols. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They may optionally contain opacifiers and may have a composition that releases the active ingredient only, or preferably, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of similar types can be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or lactose and high molecular weight polyethylene glycols.

[0512] The dosage form for the topical and / or transdermal administration of compositions can include ointment, paste, cream, lotion, gel, powder, solution, spray, inhalant and / or patch.Usually, active component is aseptically mixed with pharmaceutically acceptable excipient and / or any preservative and / or buffer that may be needed.In addition, the application has considered the use of transdermal patch, which generally has the additional advantage of providing the controlled delivery of compound to health.Such dosage form can be prepared, for example, by dissolving the compound and / or being distributed in a suitable medium.Alternatively or additionally, speed can be provided rate control membrane and / or by being dispersed in a polymer matrix and / or gel by any one of the following control.

[0513] Formulations suitable for topical administration include, but are not limited to, liquid and / or semi-liquid formulations such as liniments, lotions, oil-in-water and / or water-in-oil emulsions such as creams, ointments and / or pastes and / or solutions and / or suspensions, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the other ingredients described herein.

[0514] Pharmaceutical compositions can be prepared, packaged and / or sold in formulations suitable for pulmonary administration via the oral cavity. Such formulations can comprise dry particles of the active ingredient. Such compositions are conveniently in dry powder form for administration using a device comprising a dry powder reservoir and / or using a self-propelled solvent / powder dispensing container (e.g., a device comprising the active ingredient dissolved and / or suspended in a low-boiling-point propellant in a sealed container). Powder compositions can comprise a solid fine powder diluent, such as sugar, and are conveniently provided in unit dose form.

[0515] Low-boiling-point propellants typically include liquid propellants having a boiling point below 65°F at atmospheric pressure. Typically, the propellant may comprise 50% to 99.9% (wt / wt) of the composition, while the active ingredient may comprise 0.1% to 20% (wt / wt) of the composition. The propellant may further comprise other ingredients, such as liquid nonionic and / or solid anionic surfactants and / or solid diluents (whose particle size may be of the same order of magnitude as the particles comprising the active ingredient).

[0516] Pharmaceutical compositions formulated for pulmonary delivery can provide the active ingredient in the form of droplets of solution and / or suspension. Such preparations can be prepared, packaged and / or sold as aqueous and / or diluted alcohol solutions and / or suspensions, optionally sterile, containing the active ingredient, and can be conveniently administered using any atomization and / or atomizing device. Such preparations may further comprise one or more other ingredients, including but not limited to flavorings such as saccharin sodium, volatile oils, buffers, surfactants and / or preservatives such as methyl hydroxybenzoate. The average diameter of the droplets provided by this route of administration can be in the range of 1 nm to 200 nm.

[0517] The formulations described herein for pulmonary delivery can be used to deliver pharmaceutical compositions intranasally. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle size of 0.2 μm to 500 μm. Such a formulation is administered in the manner of snuff, i.e., by rapid inhalation through the nasal passages from a powder container held near the nose.

[0518] Preparations suitable for nasal administration can, for example, contain 0.1% (wt / wt) to 100% (wt / wt) of active ingredients, and can contain one or more other active ingredients as described herein. Pharmaceutical compositions can be prepared, packaged and / or sold in preparations suitable for buccal administration. Such preparations can, for example, be in the form of tablets and / or lozenges prepared using conventional methods, and can, for example, be 0.1% to 20% (wt / wt) of active ingredients, the remainder comprising an orally soluble and / or degradable composition, and optionally, one or more other ingredients as described herein. Alternatively, preparations suitable for oral administration can include a powder and / or atomized and / or sprayed solution and / or suspension containing the active ingredient. Such powdered, aerosolized and / or aerosolized preparations can have an average particle and / or droplet size in the range of 0.1nm to 200nm when dispersed, and can further include one or more other ingredients as described herein.

[0519] The pharmaceutical composition can be prepared, packaged and / or sold in the form of a formulation suitable for ophthalmic administration. Such formulations can, for example, be in the form of drops comprising, for example, a 0.1 / 1.0% (wt / wt) solution and / or suspension of the active ingredient in an aqueous or oily liquid excipient. Such drops may further comprise a buffer, a salt and / or one or more of any other additive ingredients described herein. Other formulations useful for ophthalmic administration include formulations comprising the active ingredient in microcrystalline form and / or in a liposomal formulation. Ear drops and / or eye drops are contemplated within the scope of the present disclosure as methods for producing polypeptides in cells.

[0520] The present application further provides a method for producing a polypeptide of interest in a mammalian cell. The method for producing the polypeptide comprises contacting the cell with a nanoparticle composition comprising an mRNA encoding the polypeptide of interest. After contacting the cell with the nanoparticle composition, the mRNA can be taken up and translated in the cell to produce the polypeptide of interest.

[0521] Typically, the step of contacting mammalian cells with a nanoparticle composition comprising an mRNA encoding a polypeptide of interest can be performed in vivo, ex vivo, in culture, or in vitro. The amount of the nanoparticle composition contacted with the cells and / or the amount of mRNA therein can depend on the type of cells or tissues being contacted, the mode of administration, the physicochemical properties of the nanoparticle composition and the mRNA (e.g., size, charge, and chemical composition), and other factors. Typically, an effective amount of the nanoparticle composition will allow for efficient production of the polypeptide in the cell. Metrics for efficiency may include polypeptide translation (represented by polypeptide expression), mRNA degradation levels, and immune response indicators.

[0522] The step of contacting the nanoparticle composition comprising the mRNA with the cell may involve or cause transfection. The phospholipids contained in the lipid component of the nanoparticle composition can promote transfection and / or increase transfection efficiency, for example, by interacting and / or fusing with the cell or intracellular membrane. Transfection can allow translation of the mRNA within the cell.

[0523] In some embodiments, the nanoparticle compositions described herein can be used for treatment. For example, the mRNA contained in the nanoparticle composition can encode a therapeutic polypeptide (e.g., in a translatable region) and produce a therapeutic polypeptide when it contacts and / or enters (e.g., transfects) a cell. In other embodiments, the mRNA contained in the nanoparticle composition can encode a polypeptide that can improve or increase the immunity of a subject. For example, the mRNA may encode granulocyte colony stimulating factor or trastuzumab.

[0524] In certain embodiments, the mRNA included in the nanoparticle composition can encode a recombinant polypeptide that can replace one or more polypeptides that may be substantially absent in the cell in contact with the nanoparticle composition. One or more substantially absent polypeptides may be absent due to genetic mutations in the encoding gene or its regulatory pathway. Alternatively, the recombinant polypeptide produced by translation of the mRNA can antagonize the activity of an endogenous protein present in the cell, on the cell surface, or secreted from the cell. Antagonistic recombinant polypeptides may be ideal to antagonize the harmful effects caused by the activity of the endogenous protein, such as localization caused by altered activity or mutation. In another alternative, the recombinant polypeptide produced by translation of the mRNA can indirectly or directly antagonize the activity of a biological moiety present in the cell, on the cell surface, or secreted from the cell. Antagonistic biological moieties may include, but are not limited to, lipids (e.g., cholesterol), lipoproteins (e.g., low-density lipoproteins), nucleic acids, carbohydrates, and small molecule toxins. The recombinant polypeptide produced by translation of the mRNA can be engineered to be localized within the cell, for example, in a specific compartment such as the nucleus, or can be engineered to be secreted from the cell or transported to the cell's plasma membrane.

[0525] In some embodiments, contacting a cell with a nanoparticle composition comprising mRNA can reduce the innate immune response of the cell to exogenous nucleic acids. The cell can be contacted with a first nanoparticle composition comprising a first amount of a first exogenous mRNA, wherein the first exogenous mRNA comprises a translatable region, and the level of the innate immune response of the cell to the first exogenous mRNA can be determined. Subsequently, the cell can be contacted with a second composition comprising a second amount of the first exogenous mRNA, wherein the second amount is a smaller amount of the first exogenous mRNA than the first amount. Alternatively, the second composition can comprise a second exogenous mRNA that is different from the first amount of the first exogenous mRNA. The step of contacting the cell with the first and second compositions can be repeated one or more times. In addition, the efficiency of polypeptide production (e.g., translation) in the cell can be optionally determined, and the cell can be repeatedly contacted with the first and / or second compositions until the target protein production efficiency is reached.

[0526] The present application further provides a method for treating a disease or condition in a mammal, the method comprising administering to the mammal a therapeutically effective amount of any of the aforementioned nanoparticle compositions, in particular, the nanoparticle composition can be used to treat a disease, condition, or illness characterized by a lack or abnormal activity of a protein or polypeptide. For example, a nanoparticle composition comprising mRNA encoding a missing or abnormal polypeptide can be administered or delivered to a cell. Subsequent translation of the mRNA can produce the polypeptide, thereby reducing or eliminating problems caused by the lack or abnormal activity of the polypeptide. Because translation can occur rapidly, these methods and compositions can be used to treat acute diseases, conditions, or illnesses such as sepsis, stroke, and myocardial infarction. The therapeutic and / or prophylactic agents included in the nanoparticle composition may also be able to alter the transcription rate of a given species, thereby affecting gene expression.

[0527] Diseases, disorders and / or conditions characterized by malfunction or aberrant protein or polypeptide activity include, but are not limited to, rare diseases, infectious diseases (such as vaccines and therapeutics), cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases, and metabolic diseases.

[0528] The present application provides methods involving the administration of nanoparticle compositions comprising one or more therapeutic and / or prophylactic agents and pharmaceutical compositions comprising nanoparticle compositions. With respect to the features and embodiments of the present application, the terms therapeutic and prophylactic are used interchangeably herein. The therapeutic composition or its imaging, diagnostic or prophylactic composition can be administered to a subject using any reasonable amount and any route of administration that is effective for preventing, treating, diagnosing or imaging a disease, disorder and / or condition and / or any other purpose. The specific dosage for a particular subject may vary depending on the type, age and general condition of the subject; the purpose of the administration; the specific ingredients; the mode of administration; etc. The compositions according to the present application can be formulated in unit dosage form for ease of administration and uniformity of dosage. However, it should be understood that the total daily dosage of the composition of the present application will be determined by the attending physician within the scope of reasonable medical judgment. The specific therapeutically effective, prophylactically effective, or other appropriate dosage level (e.g., for imaging) for any particular patient will depend on a variety of factors, including the severity and identification of the condition being treated, if any; the therapeutic and / or prophylactic agent(s) employed; the specific ingredient employed; the patient's age, weight, general health, sex, and diet; the time of administration, route of administration, and rate of excretion of the specific pharmaceutical ingredient employed; the duration of the treatment; drugs used in combination or concomitantly with the specific pharmaceutical ingredient employed; and other factors well known in the medical community.

[0529] The application further provides a method for therapeutic and / or preventative specific delivery to mammalian organs, the method comprising administering any one of the nanoparticle compositions described above to a mammal, wherein the administration comprises contacting a mammalian organ with the nanoparticle composition, thereby delivering the therapeutic and / or preventative to the organ. Therapeutic and / or preventative, for example, a protein, a cytotoxic agent, a radioactive ion, a chemotherapeutic agent, or a nucleic acid (such as RNA, for example mRNA) can be delivered to a cell or organ. In the case where therapeutic and / or preventative is mRNA, when a cell contacts the nanoparticle composition, translatable mRNA can be translated in the cell to produce a target polypeptide. However, substantially non-translatable mRNAs also can be delivered to the cell. Substantially non-translatable mRNA can be used as a vaccine and / or can isolate the translation component of a cell to reduce the expression of other species in the cell.

[0530] In some embodiments, the nanoparticle composition can be targeted to a specific type or class of cells (e.g., cells of a specific organ or system thereof). For example, a nanoparticle composition comprising a target treatment and / or prevention can be specifically delivered to the liver, kidney, spleen, femur, gastrointestinal tract, or lung of a mammal. Specific delivery to a specific class of cells, organs, or systems or groups thereof means that a higher proportion of the nanoparticle composition comprising a therapeutic and / or preventive agent, including treatment and / or prevention, is delivered to the target destination (e.g., tissue) relative to other destinations, for example, when the nanoparticle composition is administered to a mammal. In some embodiments, the target tissue is selected from the group consisting of liver, kidney, lung, spleen, femur, eye, gastrointestinal tissue (e.g., by intraocular, subretinal, or intravitreal injection), vascular endothelium in a blood vessel (e.g., intracoronary or intrafemoral) or kidney, and tumor tissue (e.g., by intratumoral injection).

[0531] As another example of targeted or specific delivery, the mRNA of protein binding partner (for example, antibody or its functional fragment, scaffold protein or peptide) or receptor on the coding cell surface can be included in the nanoparticle composition.MRNA may increase alternatively or alternatively be used to instruct the synthesis and extracellular location of lipid, carbohydrate or other biological part.Alternatively, other treatments and / or preventive agents or elements (for example, lipid or part) of nanoparticle composition can be selected based on their affinity to specific receptor (for example, low-density lipoprotein receptor) so that nanoparticle composition can interact more easily with the target cell group that comprises receptor.

[0532] In some embodiments, the ligand can be a surface-bound antibody, which can allow for the modulation of cell targeting specificity. This is particularly useful because highly specific antibodies can be generated against the target epitope of the desired targeting site. In one embodiment, multiple antibodies are expressed on the cell surface, and each antibody can have a different specificity for the desired target. This approach can improve the affinity and specificity of the targeting interaction.

[0533] Targeted cells can include, but are not limited to, hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, lung cells, bone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticular cells, leukocytes, granulocytes, and tumor cells.

[0534] In some embodiments, nanoparticle compositions can be targeted to hepatocytes.

[0535] In some embodiments, nanoparticle compositions can be targeted to extrahepatic cells.

[0536] In some preferred embodiments, nanoparticle compositions may be targeted to the spleen, stomach, or intestines.

[0537] The nanoparticle compositions of the present application can be administered by any route. In some embodiments, a composition comprising a prophylactic, diagnostic or imaging composition is administered by one or more of a variety of routes, comprising oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal or intradermal, intradermal, rectal, intravaginal, intraperitoneal, intraocular, subretinal, intravitreal, topical (e.g., by powder, ointment, cream, gel, lotion and / or drops), mucosal, nasal, buccal, intestinal, vitreous, intratumoral, sublingual, intranasal; by intratracheal instillation, bronchial instillation and / or inhalation; as an oral spray and / or powder, nasal spray and / or aerosol, and / or through a portal vein catheter. In some embodiments, the composition can be administered intravenously, intramuscularly, intradermally, intraarterially, intratumorally, subcutaneously, intraocularly, subretinally, intravitreally or by inhalation. However, in view of possible advances in drug delivery science, the present application encompasses delivery or description of the compositions described herein by any suitable route. Typically, the most suitable route of administration depends on a variety of factors, including the properties of the nanoparticle composition, including one or more therapeutic and / or preventive measures (e.g., its stability in various body environments (e.g., blood and gastrointestinal tract)), the patient's condition (e.g., whether the patient can tolerate a particular route of administration), etc.

[0538] In certain embodiments, the therapeutic and / or prophylactic agent is administered to a mammal at a dose of 0.0001 mg / kg to 10 mg / kg. For example, 0.0001 mg / kg to 10 mg / kg, 0.001 mg / kg to 10 mg / kg, 0.005 mg / kg to 10 mg / kg, 0.01 mg / kg to 10 mg / kg, 0.05 mg / kg to 10 mg / kg, 0.1 mg / kg to 10 mg / kg 1mg / kg to 10mg / kg, 2mg / kg to 10mg / kg, 5mg / kg to 10mg / kg, 0.0001mg / kg to 5mg / kg, 0.001mg / kg to 5mg / kg, 0.005mg / kg to 5mg / kg, 0.01mg / kg to 5mg / kg, 0.05mg / kg to 5mg / kg, 0.1mg / kg to 5mg / kg, 1mg / kg to 5mg / kg, 2mg / kg to 5mg / kg, 0.0001mg / kg to 2.5mg / kg, 0.001mg / kg to 2.5mg / kg, 0.005mg / kg to 2.5mg / kg, 0.01mg / kg to 2.5mg / kg 0.05mg / kg to 2.5mg / kg, 0.1mg / kg to 2.5mg / kg, 1mg / kg to 2.5mg / kg, 2mg / kg to 2.5mg / kg, 0.0001mg / kg to 1mg / kg, 0.001mg / kg to 1mg / kg, 0.005mg / kg to 1mg / kg, 0.01mg / kg to 1mg / kg, 0.05mg / kg to 1mg / kg, 0.1mg / kg to 1mg / kg, 0.0001mg / kg to 0.25mg / kg, 0.001mg / kg to 0.25mg / kg, 0.005mg / kg to 0.25mg / kg, 0.01mg / kg to 0.25mg / kg, 0.05mg / kg to 0.25mg / kg or 0.1mg / kg to 0.25mg / kg. In some embodiments, a therapeutic and / or preventive (e.g., mRNA) dose of the nanoparticle composition can be administered in a range of about 0.001 mg / kg to about 10 mg / kg. In other embodiments, a therapeutic and / or preventive dose of about 0.005 mg / kg to about 2.5 mg / kg can be administered. In certain embodiments, a dose of about 0.1 mg / kg to about 1 mg / kg can be administered. In other embodiments, a dose of about 0.05 mg / kg to about 0.25 mg / kg can be administered. The dose can be administered once or multiple times daily in the same or different amounts to obtain the desired level of mRNA expression and / or therapeutic, diagnostic, preventive, or imaging effect.The desired dose can be delivered, for example, three times a day, twice a day, once a day, every other day, every three days, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations) can be used to deliver the desired dose. In some embodiments, a single dose can be administered, for example, before or after surgery, or in the case of an acute disease, disorder, or condition.

[0539] Nanoparticle compositions comprising one or more therapeutic and / or prophylactic agents can be used in combination with one or more other therapeutic, prophylactic, diagnostic or imaging agents. "In combination with" does not mean that the agents must be administered simultaneously and / or formulated for delivery together, although these delivery methods are within the scope of this application. For example, one or more nanoparticle compositions comprising one or more different therapeutic and / or prophylactic agents can be administered in combination. The composition can be administered simultaneously with, before or after one or more other desired treatments or medical procedures. Typically, each agent will be administered at a dose and / or schedule determined for that agent. In some embodiments, the present application includes delivering a composition or its imaging, diagnostic or prophylactic composition in combination with an agent that increases its bioavailability, reduces and / or alters its metabolism, inhibits its excretion and / or regulates contraction in the body.

[0540] It should be understood that the therapeutic, prophylactic, diagnostic or imaging agents used in combination can be administered together in a single composition or separately in different compositions. Generally, it is desirable that the levels of the agents used in combination do not exceed the levels at which they are used individually. In some embodiments, the levels used in combination may be lower than the levels used individually.

[0541] The specific combination of therapies (treatments or procedures) to be used in a combination regimen will take into account the compatibility of the desired treatments and / or procedures and the desired therapeutic effect to be achieved. It will also be recognized that the therapies employed may achieve the desired effect for the same condition (e.g., a composition for treating cancer may be administered concurrently with a chemotherapeutic agent), or they may achieve different effects (e.g., controlling any side effects, such as infusion-related reactions).

[0542] In some embodiments, the method for treating a subject in need or delivering a therapeutic and / or preventive drug to a subject (e.g., mammal) may include pre-treating the subject with one or more medicaments before administering the nanoparticle composition. For example, the subject may be pre-treated with an effective dose of (e.g., 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg or any other effective dose) of dexamethasone, methotrexate, acetaminophen, H1 receptor blockers, or H2 receptor blockers. Pre-treatment may occur 24 hours or less (e.g., 24 hours, 20 hours, 16 hours, 12 hours, 8 hours, 4 hours, 2 hours, 1 hour, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or 10 minutes) before administering the nanoparticle composition, and may occur once, twice, or more times, for example, when the dosage is increased.

[0543] The various embodiments described in this application (including the examples below) and the features in each embodiment should be understood to be able to be combined with each other in any way, and the various solutions obtained by these combinations are included in the scope of this application, just as the solutions obtained by these combinations are specifically and one by one listed in this document, unless the context clearly indicates otherwise. BRIEF DESCRIPTION OF THE DRAWINGS

[0544] Figure 1. Luciferase expression results of LNP prepared based on the compound of the present invention after intramuscular injection for 24 hours.

[0545] Figures 2A-2D show the distribution of luciferase in tissues and organs after 24 hours of intravenous injection of LNPs prepared based on the compounds of the present invention.

[0546] Figures 3A-3B show liver ALT / AST levels 24 hours after intravenous injection of LNPs prepared based on the compounds of the present invention.

[0547] Example

[0548] The following examples are provided for illustrative purposes only and are not intended to limit the present invention in any way. Unless otherwise indicated, all temperatures are in degrees Celsius and pressures are at or near atmospheric pressure. Except for synthetic intermediates or otherwise noted, all reagents and raw materials used in this application were obtained from commercial sources.

[0549] Example 1 Synthesis of Compound 1

[0550] The synthetic route is shown below.

[0551] Specifically, to a solution of compound A1 (2.0 g, 8.96 mmol) in dichloromethane (30 ml) were added compound B1 (1.9 g, 7.47 mmol), DCC (1.8 g, 8.96 mmol), and DMAP (437 mg, 3.58 mmol). The mixture was stirred at room temperature for 7 hours and the reaction was monitored by TLC. After completion of the reaction, an equal volume of saturated sodium bicarbonate solution was added to dilute the reaction solution. The layers were separated, and the organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 30:1) to afford compound C1 (2.9 g, 85.00%).

[0552] To a solution of compound E1 (5.0 g, 25.63 mmol) in dichloromethane (60 ml) were added compound D1 (3.7 g, 21.36 mmol), DCC (5.29 g, 25.63 mmol), and DMAP (1.2 g, 10.25 mmol). The mixture was stirred at room temperature for 7 hours and monitored by TLC. After completion, an equal volume of saturated sodium bicarbonate solution was added to dilute the reaction solution. The layers were separated, and the organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 30:1) to afford compound F1 (6.5 g, 88.00%).

[0553] To a solution of compound F1 (500 mg, 1.44 mmol) in DMF (15 ml) were added compound G (562 mg, 2.88 mmol), NBu₄I (795 mg, 2.15 mmol), and K₂CO₃ (597 mg, 4.32 mmol). The mixture was stirred at room temperature for 12 hours and monitored by TLC. Upon completion, the reaction mixture was diluted with an equal volume of water, extracted with ethyl acetate (10 ml x 3), concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford compound H1 (580 mg, 87% yield).

[0554] To a solution of compound H1 (500 mg, 1.08 mmol) in DMF (15 ml) were added compound C1 (745 mg, 1.62 mmol), NBu4I (598 mg, 1.62 mmol), and Cs2CO3 (1.4 g, 4.32 mmol). The mixture was stirred at room temperature for 15 hours and monitored by TLC. After completion, an equal volume of water was added to dilute the mixture, followed by extraction with ethyl acetate (10 ml x 3), concentration, and silica gel column chromatography (petroleum ether:ethyl acetate = 10:1) to afford compound I1 (811 mg, 89% yield).

[0555] To a solution of compound I1 (10 g, 11.85 mmol) in dichloromethane (100 ml) was added concentrated hydrochloric acid (60 ml). The mixture was stirred at room temperature for 3 hours and the reaction was monitored by TLC. After completion of the reaction, the layers were separated and the organic layer was washed with saturated sodium bicarbonate solution, dried over anhydrous magnesium sulfate, concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 30:1) to afford compound J1 (6.5 g, 81.00%).

[0556] To a solution of compound J1 (1 g, 1.48 mmol) in toluene (25 ml) were added compound K1 (470 mg, 4.44 mmol) and pyridinium 4-methylbenzenesulfonate (744 mg, 2.96 mmol). A Dean-Stark apparatus was used and the mixture was heated under reflux for 20 hours. The reaction was monitored by TLC. After completion of the reaction, the mixture was cooled to room temperature and diluted with an equal volume of water. The mixture was extracted with ethyl acetate (10 ml x 3), concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to afford compound L1 (648 mg, 57% yield).

[0557] To a solution of compound L1 (750 mg, 0.98 mmol) in ultra-dry dichloromethane (10 ml) at 0°C was added methylsulfonic anhydride (340 mg, 1.96 mmol) and anhydrous triethylamine (0.45 ml). The mixture was stirred for 12 hours and the reaction was monitored by TLC. After the reaction was complete, the mixture was allowed to cool to room temperature and diluted with an equal volume of water. The layers were separated, and the organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to afford compound M1 (800 mg, 97% yield).

[0558] To compound M1 (750 mg, 0.89 mmol) was added 30 ml of dimethylamine (2 M in THF), sealed, and stirred at room temperature for 6 days. The reaction was monitored by TLC. After completion of the reaction, the mixture was concentrated and purified by silica gel column chromatography (dichloromethane:methanol = 30:1) to afford compound 1 (212 mg, 30% yield) as an oil. 1 H NMR (600MHz, CDCl3) δ4.87–4.82(m,1H),4.05–4.02(m,2H),3.90–3.85(m,2H),3.59–3.56(m,2H),2.31–2.23(m,4H),2 .21–2.19(m,8H),1.94–1.87(brs,1H),1.68–1.56(m,10H),1.52–1.42(m,4H),1.36–1.21(m,52H),0.87–0.84(m,9H); 13C NMR (151MHz, CDCl3) δ173.98,173.77,100.76,74.22,64.55,62.87,62.81,59.34,59.3 1,45.97,35.37,35.28,34.86,34.49,34.46,34.28,32.47,32.39,32.03,31.99,29.99 29.72,29.65,29.46,29.36,28.80,26.06,25.44,25.29,25.16,23.49,23.26,23.16,22.92,22.79,14.22; MS-ESI(m / z):794.6(M+H) + .

[0559] Example 2 Synthesis of Compound 2

[0560] The preparation method is the same as compound 1, but 1,2,4-butanetriol is used instead of compound K1 as the raw material to obtain oily compound 2. 1 H NMR(600MHz, CDCl3)δ4.82–4.78(m,1H),4.04–3.96(m,4H),3.42–3.39(m,1H),2.39–2.34(brs,1H),2.29–2.25(brs,1H), 2.23–2.18(m,10H),1.77–1.71(brs,1H),1.66–1.65(brs,1H),1.58–1.39(m,13H),1.33–1.16(m,53H),0.82–0.80(m,9H); 13 C NMR (151MHz, CDCl3) δ173.62,173.41,111.82,74.63,74.61,73.88,69.89,64.25,56.18,45. 28,37.73,37.48,37.40,37.20,34.59,34.19,34.18,34.09,31.83,31.78,31.60,29.70,29. 68,29.52,29.50,29.45,29.34,29.32,29.25,29.20,29.15,29.09,29.07,28.59,25.86,25. 23,25.07,24.89,23.88,23.58,23.56,23.24,22.60,22.58,14.01; MS-ESI(m / z):794.6(M+H) + .

[0561] Example 2A Synthesis of Compound 2A

[0562] The preparation method is the same as compound 1, but (S)-1,2,4-butanetriol is used instead of compound K1 as the raw material to obtain oily compound 2A. 1 H NMR (400MHz, CDCl3) δ4.97-4.83(m,1H),4.17–4.05(m,4H),3.52(t,J=8.0Hz,1H),2.58–2.37(m,2H), 2.35–2.23(m,10H),1.91–1.70(m,2H),1.69–1.50(m,14H),1.48–1.24(m,52H),0.92(t,J=8.0Hz,9H); 13 C NMR (100MHz, CDCl3) δ174.04,173.69,112.10,74.59,74.12,69.94,64.34,56.22,4 5.21,37.79,37.70,37.44,37.38,34.74,34.42,34.16,31.91,31.88,31.43,31.41, 29.80,29.57,29.55,29.52,29.49,29.32,29.28,29.25,29.19,28.63,28.61,25.95 ,25.33,25.17,25.00,23.89,23.71,23.59,22.68,14.12; MS-ESI(m / z):795.0(M+H) + .

[0563] Example 3 Synthesis of Compound 3

[0564] The preparation method is the same as compound 1, but using 3-dimethylamino-1,2-propanediol and p-toluenesulfonic acid monohydrate instead of compound K1 and 4-methylbenzenesulfonic acid pyridinium as raw materials to obtain oily compound 3. 1 H NMR (600MHz, CDCl3) δ4.85–4.81(m,1H),4.20–4.16(m,1H),4.06–4.01(m,3H),3.49–3.46(m,1H),2.48–2.44(m,1H), 2.35–2.32(m,1H),2.27–2.22(m,10H),1.60–1.54(m,8H),1.48–1.47(m,4H),1.31–1.20(m,54H),0.86–0.83(m,9H); 13C NMR (151MHz, CDCl3) δ173.90,173.69,112.58,74.40,74.36,74.13,69.06,64.48,62.62,62.5 9,46.22,37.80,37.55,37.51,37.30,34.79,34.40,34.38,34.24,31.99,31.94,29.88,29.83, 29.68,29.66,29.61,29.58,29.52,29.47,29.41,29.38,29.33,29.31,29.27,29.25,28.74,26 .01,25.39,25.24,25.06,25.06,24.03,23.70,23.35,22.74,14.17; MS-ESI(m / z):780.6(M+H) + .

[0565] Example 4 Synthesis of Compound 4

[0566] The preparation method is the same as compound 1, using undecanoic acid and 6-bromo-1-hexanol instead of compound D1 and compound E1 as raw materials to obtain oily compound 4. 1 H NMR (600MHz, CDCl3) δ4.86–4.81(m,1H),4.04–4.01(m,2H),3.90–3.84(m,2H),3.59–3.55(m,2H),2.27–2.22(m,4H),2 .20–2.17(m,8H),1.94–1.85(brs,1H),1.67–1.55(m,10H),1.48–1.45(m,4H),1.36–1.22(m,52H),0.86–0.83(m,9H); 13 C NMR (151MHz, CDCl3) δ174.01,173.70,100.73,74.14,64.40,64.36,62.83,62.75,59.31,5 9.28,45.98,35.50,35.25,34.79,34.47,34.24,32.45,32.43,32.22,31.98,31.95,29.94, 29.70,29.64,29.61,29.59,29.55,29.42,29.39,29.35,29.32,29.29,29.25,28.73,26.05 ,25.40,25.24,25.10,23.45,23.32,23.21,23.08,22.75,14.18; MS-ESI(m / z):794.6(M+H)+ .

[0567] Example 5 Synthesis of Compound 5

[0568] The preparation method is the same as compound 1, using undecanoic acid, 6-bromo-1-hexanol and 1,2,4-butanetriol instead of compound D1, compound E1 and compound K1 as raw materials to obtain oily compound 5. 1 H NMR (600MHz, CDCl3) δ4.81(p,J=6.2Hz,1H),4.03(t,J=6.6Hz,1H),3.99(t,J=6.6Hz,3H),3.42(t,J=7.6Hz,1H),2.41–2.36(brs,1H),2.31–2 .26(brs,1H),2.23–2.20(m,10H),1.78–1.73(brs,1H),1.66–1.60(brs,1H),1.58–1.43(m,12H),1.31–1.20(m,54H),0.82(t,J=7.0Hz,9H); 13 C NMR (151MHz, CDCl3) δ173.92,173.60,112.00,74.75,74.73,74.05,70.00,64.31,56.2 9,45.41,37.83,37.73,37.50,37.42,34.73,34.40,34.20,31.93,31.90,31.73,31.71, 29.82,29.80,29.58,29.56,29.53,29.50,29.33,29.30,29.26,29.20,28.67,28.65,25 .96,25.35,25.19,25.05,23.90,23.71,23.59,22.69,14.13; MS-ESI(m / z):794.6(M+H) + .

[0569] Example 5A Synthesis of Compound 5A

[0570] The preparation method is the same as compound 1, using undecanoic acid, 6-bromo-1-hexanol and (S)-1,2,4-butanetriol instead of compound D1, compound E1 and compound K1 as raw materials to obtain oily compound 5A. 1H NMR (400MHz, CDCl3) δ4.97-4.83(m,1H),4.17–4.06(m,4H),3.51(t,J=4.0Hz,1H),2.51–2.45(m,1H),2.44–2.32(m,1H), 2.31–2.23(m,10H),1.87–1.80(m,1H),1.74–1.67(m,1H),1.66–1.50(m,14H),1.48–1.24(m,52H),0.92(t,J=8.0Hz,9H); 13 C NMR (100Hz, CDCl3) δ173.96,173.62,111.98,74.71,74.08,69.96,64.30,56.24,4 5.36,37.60,37.53,37.50,37.43,34.71,34.39,34.13,31.87,31.84,31.67,31.6 1,29.78,29.70,29.51,29.48,29.30,29.28,29.24,29.18,28.64,28.61,25.94,2 5.32,25.17,25.03,23.89,23.70,23.59,22.67,14.11; MS-ESI(m / z):795.0(M+H) + .

[0571] Example 5B Synthesis of Compound 5B

[0572] The preparation method is the same as compound 1, using undecanoic acid, 6-bromo-1-hexanol and (R)-1,2,4-butanetriol instead of compound D1, compound E1 and compound K1 as raw materials to obtain oily compound 5B. 1 H NMR (400MHz, CDCl3) δ4.97-4.83(m,1H),4.17–4.05(m,4H),3.51(t,J=4.0Hz,1H),2.51–2.45(m,1H),2.44–2.32(m,1H), 2.31–2.23(m,10H),1.86–1.80(m,1H),1.74–1.67(m,1H),1.66–1.51(m,14H),1.48–1.24(m,52H),0.92(t,J=8.0Hz,9H); 13C NMR (100MHz, CDCl3) δ173.97,173.62,111.98,74.71,74.08,69.96,64.30,56.24, 45.36,37.60,37.43,37.50,37.44,34.71,34.39,34.13,31.87,31.84,31.67,31. 61,29.79,29.70,29.51,29.48,29.30,29.28,29.24,29.18,28.64,28.61,25.94, 25.32,25.18,25.03,23.89,23.70,23.59,22.67,14.11; MS-ESI(m / z):795.0(M+H) + .

[0573] Example 6 Synthesis of Compound 6

[0574] The preparation method is the same as compound 1, using undecanoic acid, 6-bromo-1-hexanol and 3-dimethylamino-1,2-propanediol instead of compound D1, compound E1 and compound K1 as raw materials to obtain oily compound 6. 1 H NMR (500MHz, CDCl3) δ4.84(p,J=6.2Hz,1H),4.19(p,J=6.5Hz,1H),4.06–4.01(m,3H),3.49(t,J=7.8Hz,1H),2.48(dd,J=12.6,6.8Hz,1 H),2.35(dd,J=12.6,5.0Hz,1H),2.27–2.23(m,10H),1.62–1.53(m,10H),1.49–1.46(m,4H),1.33–1.24(m,52H),0.85(t,J=6.8Hz,9H); 13 C NMR (126MHz, CDCl3) δ174.05,173.72,112.66,74.44,74.18,69.08,64.40,62.65,46.25,37.8 2,37.71,37.49,37.44,34.83,34.50,34.26,32.00,31.97,29.91,29.86,29.63,29.61,29.40, 29.37,29.33,29.27,28.73,26.04,25.42,25.26,25.12,24.06,23.95,23.73,23.61,22.77,14.19; MS-ESI(m / z):780.6(M+H) + .

[0575] Example 7 Synthesis of Compound 7

[0576] The preparation method is the same as compound 1, using 8-bromo-1-octanol, 2-octyl-decanoic acid and 3-dimethylamino-1,2-propylene glycol instead of compound A1, compound B1 and compound K1 as raw materials to obtain oily compound 7. 1 H NMR (500MHz, CDCl3) δ4.22–4.17(m,1H),4.06–4.01(m,5H),3.48(t,J=7.8Hz,1H),2.50–2.46(m,1H),2.39–2.3 6(m,1H),2.28–2.24(m,9H),1.60–1.53(m,13H),1.42–1.37(m,2H),1.30–1.22(m,53H),0.85(t,J=6.8Hz,9H); 13 C NMR (126MHz, CDCl3) δ176.64,173.92,112.62,74.26,74.21,68.96,64.29,64.1 0,62.48,46.07,45.85,37.75,37.60,37.42,37.32,34.40,32.56,31.90,31.87, 29.91,29.86,29.57,29.46,29.31,29.25,29.18,28.75,28.64,27.47,25.99,25 .94,25.03,23.98,23.85,23.64,23.51,22.67,14.10; MS-ESI(m / z):794.6(M+H) + .

[0577] Example 8 Preparation of Compound 8

[0578] The preparation method is the same as compound 1, using 8-bromo-1-octanol, 2-octyl-decanoic acid and 1,2,4-butanetriol instead of compound A1, compound B1 and compound K1 as raw materials to obtain oily compound 8. 1 H NMR (500MHz, CDCl3) δ4.07–4.00 (m, 6H), 3.44 (t, J = 7.5Hz, 1H), 2.42–2.36 (brs 1H),2.32–2.21(m,10H),1.81–1.74(brs,1H),1.68–1.51(m,14H),1.42–1.34(brs,2H),1.26–1.22(m,53H),0.84(t,J=6.9Hz,9H); 13C NMR (126MHz, CDCl3) δ176.69,173.97,112.05,74.81,70.06,64.36,64.16,5 6.36,45.92,45.50,37.93,37.78,37.59,37.48,34.46,32.63,31.97,31.94, 31.82,29.63,29.53,29.37,29.32,29.24,28.81,28.71,27.54,26.06,26.02 ,25.09,24.07,23.94,23.77,23.64,22.73,14.16; MS-ESI(m / z):808.6(M+H) + .

[0579] Example 9 Preparation of Compound 9

[0580] The preparation method is the same as compound 1, using 8-bromo-1-octanol, 2-octyl-decanoic acid, undecanoic acid and 6-bromo-1-hexanol instead of compound A1, compound B1, compound D1 and compound E1 as raw materials to obtain oily compound 9. 1 H NMR (500MHz, CDCl3) δ4.04–4.01(m,4H),3.89–3.85(m,2H),3.59–3.56(m,2H),2.31–2.18(m ,11H),1.93–1.86(brs,1H),1.67–1.52(m,12H),1.43–1.23(m,56H),0.85(t,J=6.9Hz,9H); 13 C NMR (126MHz, CDCl3) δ176.71,174.00,100.75,64.40,64.36,64.18,62.83,62.76,59.34,59.31F,45.98,45.94,35.46,35.25,34.48,3 2.64,32.54,32.46,32.34,31.98,31.96,30.06,29.71,29.65,29.55,29.39,29.34,29.26,28.83,28.74,27.56,26.08,25.11,23.46, 23.32,23.23,23.09,22.75,14.18; MS-ESI(m / z):808.5(M+H) + .

[0581] Example 10 Preparation of Compound 10

[0582] The preparation method is the same as compound 1, but using 1,2,4-butanetriol and N-ethylmethylamine instead of compound K1 and dimethylamine as raw materials to obtain oily compound 10. 1 H NMR (600MHz, CDCl3) δ4.83–4.75(m,1H),4.05–3.93(m,4H),3.42–3.35(m,1H),2.46-2.30(m,4H),2.23–2.15(m,7H),1.79–1.70(m, 1H),1.67–1.59(m,1H),1.56–1.51(m,6H),1.43(d,J=7.2Hz,4H),1.29–1.14(m,56H),0.99(t,J=7.1Hz,3H),0.80(t,J=7.0Hz,9H); 13 C NMR (151MHz, CDCl3) δ173.72,173.51,111.83,74.85,74.81,73.96,69.99,64.33,53.70,51.4 3,41.49,37.80,37.56,37.48,37.28,34.66,34.26,34.25,34.15,31.90,31.85,31.30,29.77, 29.59,29.57,29.51,29.49,29.41,29.38,29.32,29.29,29.24,29.22,29.16,29.13,28.65,25 .92,25.30,25.13,24.97,23.96,23.66,23.31,22.65,14.08,12.09; MS-ESI(m / z):808.7(M+H) + .

[0583] Example 11 Preparation of Compound 11

[0584] The preparation method is the same as compound 1, except that 1,2,4-butanetriol and diethylamine are used as raw materials instead of compound K1 and dimethylamine to obtain oily compound 11. 1H NMR (600 MHz, CDCl3) δ 4.86–4.80 (m, 1H), 4.08–4.00 (m, 4H), 3.49–3.43 (m, 1H), 2.77–2.62 (m, 7H), 2.25 (dt, J = 10.5, 7.5 Hz, 4H), 1.85–1.75 (m, 2H), 1.63–1.56 (m, 6H), 1.50–1.44 (m, 4H), 1.37–1.19 (m, 56H), 1.12 (t, J = 7.2 Hz, 6H), 0.85 (td, J = 7.1, 2.4 Hz, 9H); 13C NMR (151MHz, CDCl3) δ173.95,173.73,112.22,74.59,74.55,74.17,69.94,64.52,49.36,46 .95,37.84,37.59,37.42,37.21,34.80,34.39,34.24,31.99,31.95,30.30,29.87,29.69,2 9.67,29.62,29.59,29.50,29.47,29.42,29.35,29.32,29.29,29.26,28.74,26.02,25.40, 25.24,25.07,24.09,23.82,23.76,23.47,22.75,14.20,10.74; MS-ESI(m / z):822.9(M+H)+.

[0585] Example 12 Preparation of Compound 12

[0586] The preparation of compound 12 refers to the preparation of compound 2.

[0587] Example 13 Preparation of Compound 13

[0588] The preparation method is the same as compound 1, but 1,2,5-pentanetriol is used instead of compound K1 as the raw material to obtain oily compound 13. 1 H NMR (600MHz, CDCl3) δ4.81–4.74(m,1H),4.00–3.92(m,4H),3.38–3.33(m,1H),2.25–2.17(m,6H),2 .15(s,6H),1.59–1.46(m,15H),1.46–1.37(m,5H),1.29–1.12(m,50H),0.79(td,J=7.1,2.3Hz,9H); 13C NMR (151MHz, CDCl3) δ173.69,173.47,111.86,76.08,76.05,73.92,69.93,69.91,F64.29,59.48,53 .38,45.24,37.80,37.56,37.47,37.25,34.64,34.24,34.22,34.13,31.88,31.83,31.20,29.76,29. 57,29.55,29.49,29.47,29.39,29.37,29.30,29.27,29.22,29.20,29.14,29.11,28.63,25.90,25. 28,25.12,24.95,23.95,23.89,23.64,23.62,23.29,22.64,22.62,14.05; MS-ESI(m / z):808.8(M+H) + .

[0589] Example 14 Preparation of Compound 14

[0590] The preparation method is the same as compound 1, but 1,2,6-hexanetriol is used instead of compound K1 as the raw material to obtain oily compound 14. 1 H NMR (600MHz, CDCl3) δ4.91–4.79(m,1H),4.02(m,4H),3.45–3.34(m,1H),2.33(t,J=6.5Hz ,2H),2.27(m,10H),1.60(m,9H),1.53–1.41(m,8H),1.25(m,55H),0.87(t,J=7.0Hz,9H); 13 C NMR(151MHz,Chloroform-d)δ111.89,76.18,74.09,70.03,64.42,59.48,45.20,37.94–37.16(m),34.73,34.33,34.15,33.31,31.88 ,29.81,29.59,29.51,29.44,29.32,29.24,28.66,27.37,25.92,25.31,25.16,24.99,23.68,22.66,14.09; MS-ESI(m / z):822.9(M+H) + .

[0591] Example 15 Preparation of Compound 15

[0592] The preparation method is the same as compound 1, but using 1,2,4-butanetriol and N-methyl-n-propylamine instead of compound K1 and dimethylamine as raw materials to obtain oily compound 15. 1 H NMR (600MHz, CDCl3) δ4.84–4.78(m,1H),4.07–3.97(m,4H),3.42(t,J=7.7Hz,1H),2.53–2.39(m,2H),2.33(t,J=7.6Hz,2H),2.26–2.20( m,7H),1.81–1.74(m,1H),1.74–1.66(m,1H),1.61–1.54(m,6H),1.51–1.41(m,5H),1.35–1.14(m,55H),0.84(dt,J=15.0,7.3Hz,12H).; 13 C NMR (151MHz, CDCl3) δ173.86,173.64,111.97,74.82,74.78,74.09,70.02,64.45,59.66,54.18, 41.99,37.87,37.62,37.52,37.32,34.76,34.35,34.22,31.97,31.92,31.06,29.85,29.83,29. 64,29.58,29.56,29.49,29.46,29.39,29.31,29.29,29.25,29.22,28.72,25.99,25.37,25.21, 25.04,24.05,23.75,23.72,23.41,22.73,22.71,20.09,14.15,11.84; MS-ESI(m / z):822.8(M+H) + .

[0593] Example 16 Preparation of Compound 16

[0594] The preparation method is the same as compound 1, but using 1,2,4-butanetriol and N-ethylisopropylamine instead of compound K1 and dimethylamine as raw materials to obtain oily compound 16. 1 H NMR(600MHz, CDCl3) δ4.84(p,J=6.3Hz,1H),4.11–4.01(m,4H),3.47(t,J=7.6Hz,1H),3. 34–2.50(m,5H),2.29–2.22(m,4H),1.64–1.44(m,14H),1.40–1.03(m,63H),0.86(t,9H); 13C NMR (151MHz, CDCl3) δ173.95,173.73,112.18,74.58,74.19,69.97,64.54,46.37,44.49,37. 86,37.61,37.44,37.23,34.82,34.41,34.25,32.01,31.97,29.90,29.87,29.80,29.70,29. 68,29.63,29.60,29.50,29.43,29.36,29.33,29.28,28.76,26.03,25.42,25.25,25.10,25. 08,24.12,23.85,23.79,23.50,22.78,22.76,18.33,17.19,14.20; MS-ESI(m / z):836.8(M+H) +

[0595] Example 17 Preparation of Compound 17

[0596] Specifically, to a solution of compound A1 (5.24 g, 23.49 mmol) in dichloromethane (30 ml) were added compound B2 (5.0 g, 19.57 mmol), EDCI (4.9 g, 25.44 mmol), and DMAP (0.96 g, 7.83 mmol). The mixture was stirred at room temperature for 7 hours and the reaction was monitored by TLC. After completion of the reaction, an equal volume of saturated sodium bicarbonate solution was added to dilute the reaction solution. The layers were separated, and the organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 30:1) to afford compound C2 (7.19 g, 80.00%).

[0597] To a solution of compound D2 (7.0 g, 40.8 mmol) in dichloromethane (60 ml) were added compound E1 (9.6 g, 49.0 mmol), EDCI (10.2 g, 53.1 mmol), and DMAP (2.0 g, 16.4 mmol). The mixture was stirred at room temperature for 7 hours and monitored by TLC. After completion, an equal volume of saturated sodium bicarbonate solution was added to dilute the reaction solution. The layers were separated, and the organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 30:1) to afford compound F2 (12.20 g, 86.15%).

[0598] To a solution of compound F2 (12.2 g, 35.14 mmol) in DMF (50 ml) were added compound G1 (13.72 g, 70.28 mmol), NBu₄I (13.0 g, 35.14 mmol), and K₂CO₃ (14.57 g, 105.43 mmol). The mixture was stirred at room temperature for 12 hours and monitored by TLC. Upon completion, the reaction mixture was diluted with an equal volume of water, extracted with ethyl acetate (50 ml x 3), concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 3:1) to afford compound H₂ (9.9 g, 61.11% yield).

[0599] To a solution of compound H2 (9.9 g, 21.42 mmol) in DMF (100 ml) were added compound C2 (11.19 g, 33.12 mmol), NBu4I (8.0 g, 21.24 mmol), and Cs2CO3 (14 g, 42.84 mmol). The mixture was stirred at room temperature for 15 hours and monitored by TLC. After completion, an equal volume of water was added to dilute the mixture, followed by extraction with ethyl acetate (100 ml x 3), concentration, and silica gel column chromatography (petroleum ether:ethyl acetate = 3:1) to afford compound I2 (12 g, 66.67% yield).

[0600] To a solution of compound I2 (12 g, 14.26 mmol) in dichloromethane (100 ml) was added concentrated hydrochloric acid (60 ml). The mixture was stirred at room temperature for 3 hours and the reaction was monitored by TLC. After completion of the reaction, the layers were separated and the organic layer was washed with saturated sodium bicarbonate solution, dried over anhydrous magnesium sulfate, concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 1:1) to afford compound G2 (7.72 g, 80.00%).

[0601] Compound K2 (1.42 g, 13.32 mmol) and pyridinium 4-methylbenzenesulfonate (1.34 g, 6.65 mmol) were added to a toluene (25 ml) solution of compound G2 (3 g, 4.44 mmol). A Dean-Stark apparatus was used and the mixture was heated under reflux for 20 hours. The reaction was monitored by TLC. After completion of the reaction, the mixture was cooled to room temperature and diluted with an equal volume of water. The mixture was extracted with ethyl acetate (50 ml x 3), concentrated, and purified by silica gel column chromatography (dichloromethane:methanol = 40:1) to afford compound L2 (1.3 g, 43.33% yield).

[0602] To a solution of compound L2 (1.3 g, 1.7 mmol) in ultra-dry dichloromethane (10 ml) at 0°C, methylsulfonic anhydride (0.59 g, 3.4 mmol) and anhydrous triethylamine (0.7 ml) were added. The mixture was stirred for 12 hours and monitored by TLC. After completion of the reaction, the mixture was allowed to cool to room temperature and diluted with an equal volume of water. The layers were separated, and the organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (dichloromethane:methanol = 40:1) to afford compound M2 (1.32 g, 92.30% yield).

[0603] To compound M2 (1.32 g, 1.57 mmol) was added 30 ml of dimethylamine (2 M in THF), sealed, and stirred at room temperature for 6 days. The reaction was monitored by TLC. After completion, the mixture was concentrated and purified by silica gel column chromatography (dichloromethane:methanol = 30:1 + aqueous ammonia) to afford compound 17 (300 mg, 24% yield) as an oil. 1 H NMR(500MHz,Chloroform-d)δ5.84–5.69(m,1H),5.34(t,J=9.1Hz,1H),4.05–3.96(m, 2H),3.88–3.79(m,1H),3.41(t,J=7.4Hz,1H),3.16(q,J=6.7Hz,2H),2.44–2.33(m,1H ),2.29–2.22(m,1H),2.19(d,J=3.3Hz,6H),2.09(t,J=7.6Hz,4H),1.79–1.69(m,1H), 1.66–1.47(m,8H),1.45–1.37(m,3H),1.30–1.17(m,56H),0.82(t,J=6.9,2.4Hz,9H); 13 C NMR (126MHz, CDCl3) δ172.97,172.62,111.98,111.94,74.72,74.68,69.97,56.31,49 .09,45.48,45.45,39.53,37.71,37.49,37.38,37.25,37.11,36.74,36.72,35.33,31. 93,31.90,31.75,29.73,29.63,29.59,29.48,29.36,29.30,29.24,26.99,25.99,25.9 4,25.80,25.76,23.92,23.77,23.60,23.40,22.69,14.14; MS-ESI(m / z):792.9(M+H)+

[0604] Example 18 Compound 18

[0605] The synthetic route is shown below.

[0606] Specifically, to a solution of compound A1 (10.40 g, 46.82 mmol) in dichloromethane (100 ml) were added compound B1 (10 g, 39.02 mmol), EDCI (14.96 g, 78.04 mmol), and DMAP (1.90 g, 15.61 mmol). The mixture was stirred at room temperature for 7 hours and the reaction was monitored by TLC. After the reaction was complete, an equal volume of saturated sodium bicarbonate solution was added to dilute the reaction solution. The layers were separated, and the organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 30:1) to obtain compound C1 (15 g, 83.52%).

[0607] To a solution of compound C1 (15 g, 32.60 mmol) in DMF (100 ml) were added compound G1 (2.12 g, 10.86 mmol), NBu₄I (4 g, 10.86 mmol), and Cs₂CO₃ (10.62 g, 32.6 mmol). The mixture was stirred at room temperature for 12 hours and monitored by TLC. After completion, an equal volume of water was added to dilute the mixture, followed by extraction with ethyl acetate (100 ml x 3). The mixture was concentrated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 40:1) to afford compound I3 (7.95 g, 76.60% yield).

[0608] To a solution of compound I3 (7.95 g, 8.31 mmol) in dichloromethane (100 ml) was added concentrated hydrochloric acid (60 ml). The mixture was stirred at room temperature for 3 hours and the reaction was monitored by TLC. After completion of the reaction, the layers were separated and the organic layer was washed with saturated sodium bicarbonate solution, dried over anhydrous magnesium sulfate, concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 50:1) to afford compound J3 (5.89 g, 89.65%).

[0609] Compound K2 (2.4 g, 22.35 mmol) and pyridinium 4-methylbenzenesulfonate (2.95 g, 11.73 mmol) were added to a solution of compound J3 (5.89 g, 7.45 mmol) in toluene (25 ml). A Dean-Stark apparatus was used and the mixture was heated under reflux for 20 hours. The reaction was monitored by TLC. After completion of the reaction, the mixture was cooled to room temperature and diluted with an equal volume of water. The mixture was extracted with ethyl acetate (50 ml x 3), concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to afford compound L3 (2.94 g, 44.95% yield).

[0610] To a solution of compound L3 (2.94 g, 3.34 mmol) in ultra-dry dichloromethane (10 ml) at 0°C was added methylsulfonic anhydride (1.2 g, 6.68 mmol) and anhydrous triethylamine (0.8 ml). The mixture was stirred for 12 hours and monitored by TLC. After completion of the reaction, the mixture was allowed to cool to room temperature and diluted with an equal volume of water. The layers were separated, and the organic layer was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to afford compound M3 (3.1 g, 97% yield).

[0611] To compound M3 (3.1 g, 3.24 mmol) was added 30 ml of dimethylamine (2 M in THF), sealed, and stirred at room temperature for 6 days. The reaction was monitored by TLC. After completion, the reaction was concentrated and purified by silica gel column chromatography (dichloromethane:methanol = 40:1) to afford compound 18 (439 mg, 14.98% yield) as an oil. 1H NMR (500MHz, CDCl3) δ4.87–4.79(m,2H),4.08–3.98(m,2H),3.44(t,J=7.4Hz,1H),2.46–2.37(m,1H),2.36–2.27(m,1H),2.22(t,J=6. 7Hz,10H),1.83–1.74(m,1H),1.72–1.62(m,1H),1.58–1.51(m,3H),1.46(d,J=6.1Hz,8H),1.36–1.14(m,69H),0.84(t,J=6.9Hz,12H); 13 C NMR (126MHz, CDCl3) δ173.69,112.11,74.73,74.10,70.02,56.33,45.42,37.85,37.53,34.78,34.23,31 .94,31.70,29.87,29.60,29.31,29.27,29.24,25.39,25.23,24.05,23.75,22.74,14.18; MS-ESI(m / z): 906.9(M+H)+.

[0612] Example 19 Compound 19

[0613] The preparation method is the same as compound 18, except that 6-bromohexanoic acid and undecanol are used as raw materials instead of compound A1 and compound B1 to obtain oily compound 19. 1H NMR (500 MHz, CDCl3) δ 4.08–3.98 (m, 6H), 3.44 (t, J = 7.4 Hz, 1H), 2.46–2.38 (m, 1H), 2.37–2.29 (m, 1H), 2.29–2.20 (m, 10H), 1.83–1.74 (m, 1H), 1.72–1.65 (m, 1H), 1.61–1.52 (m, 11H), 1.29–1.22 (m, 41H), 0.85 (t, J = 6.9 Hz, 6H); 13 C NMR (126MHz, CDCl3) δ173.94,111.93,74.78,70.07,64.50,56.33,45.44,37.67,37.39,34.39,31.99,31.67,2 9.68,29.61,29.50,29.42,29.34,28.74,26.01,25.06,23.75,23.42,22.77,14.21; MS-ESI(m / z):628.6(M+H)+

[0614] Example 20A Compound 20A

[0615] The synthetic route is shown below.

[0616] Specifically, to a solution of compound A1 (0.28 g, 1.25 mmol) in dichloromethane (30 ml) were added compound B4 (0.25 g, 1.25 mmol), DCC (0.28 g, 1.38 mmol), and DMAP (0.01 g, 0.06 mmol). The mixture was stirred at room temperature for 2 hours and the reaction was monitored by TLC. After completion, the reaction solution was diluted with an equal volume of saturated sodium bicarbonate solution. The layers were separated, and the organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 30:1) to afford compound C4 (0.50 g, 88.90%).

[0617] To a solution of compound C4 (0.50 g, 1.23 mmol) in DMF (5 ml) was added compound G1 (0.12 g, 0.62 mmol), NBu4I (0.05 g, 0.12 mmol), and Cs2CO3 (1.21 g, 3.71 mmol). The mixture was stirred at room temperature for 12 hours and monitored by TLC. Upon completion, the reaction mixture was diluted with an equal volume of water, extracted with ethyl acetate (10 ml x 3), and concentrated to afford crude compound I4, which was used directly in the next step.

[0618] To a solution of compound I4 (crude, 1.23 mmol) in dichloromethane (10 mL) was added concentrated hydrochloric acid (5 mL). The mixture was stirred at room temperature for 3 hours and the reaction was monitored by TLC. Upon completion of the reaction, the layers were separated, and the organic layer was washed with saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 30:1) to afford compound J4 (0.27 g, 32.27% yield over two steps).

[0619] To a solution of compound J4 (0.27 g, 0.40 mmol) in toluene (25 ml) were added compound K2 (0.17 g, 1.59 mmol) and pyridinium 4-methylbenzenesulfonate (0.10 g, 0.02 mmol). A Dean-Stark apparatus was used and the mixture was heated under reflux for 20 hours. The reaction was monitored by TLC. After completion, the mixture was cooled to room temperature and diluted with an equal volume of water. The mixture was extracted with ethyl acetate (10 ml x 3), concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to afford compound L4 (0.28 g, 91.79% yield).

[0620] To a solution of compound L4 (0.28 g, 0.36 mmol) in dichloromethane (10 ml) was added methylsulfonic anhydride (0.10 g, 0.55 mmol) and anhydrous triethylamine (0.20 ml). The mixture was stirred at room temperature for 2 hours and monitored by TLC. After the reaction was complete, the mixture was allowed to cool to room temperature and diluted with an equal volume of water. The layers were separated and the organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain crude compound M4, which was used directly in the next step.

[0621] To compound M4 (crude, 0.36 mmol) was added 20 ml of a 2 M dimethylamine solution in THF. The mixture was stirred at room temperature for 3 days under a nitrogen atmosphere and monitored by TLC. After completion, the reaction was concentrated and purified by silica gel column chromatography (dichloromethane:methanol = 30:1) to afford compound 20A (0.21 g, 66.50% yield over two steps) as an oil. 1H NMR (400MHz, CDCl3) δ4.20–4.09(m,6H),3.55(t,J=8.0Hz,1H),2.87–2.69(m,2H),2.55(s,6H),2.32( 13C NMR (400MHz, CDCl3) δ173.96,112.52,73.98,69.66,62.94,55.97,44.30,37.66,37.17,34.63,34.42,33.57,32.49,32.23,29.73 29.71,29.27,29.14,26.21,24.98,23.97,23.71,22.66,14.09; MS-ESI(m / z):795.0(M+H)+.

[0622] Example 21 Compound 21

[0623] The preparation method is the same as compound 18, using 6-bromohexanol and 2-hexyldecanoic acid instead of compound A1 and compound B1 as raw materials to obtain oily compound 21. 1 H NMR(600MHz,Chloroform-d)δ4.11–4.02(m,6H),3.47(t,J=7.6Hz,1H),2.47–2.41(brs,1H),2.37–2.33(brs,1H),2.32–2.24(m,8H),1.84–1.7 8(brs,1H),1.72–1.65(brs,1H),1.63–1.54(m,12H),1.45–1.40(m,4H) ,1.37–1.31(m,10H),1.30–1.21(m,42H),0.87(td,J=7.0,1.3Hz,12H); 13C NMR (600MHz, Chloroform-d) δ176.70,111.95,74.72,69.98,64.08,56.24,45.84,45.34,37.75,37.43,32.52,31.85,31.69, 31.62,29.56,29.44,29.24,29.22,28.69,27.46,27.41,25.99,23.90,23.60,22.66,22.58,14.07; MS-ESI(m / z):823.0(M+H)+.

[0624] Test example

[0625] Test Example 1 Lipid Nanoparticle (LNP) Encapsulation

[0626] The mRNA stock solution was dispersed in 20mM acetic acid solution (pH5.0) to a final concentration of 200μg / mL (aqueous phase). According to the molar ratio of the compounds in Table 1: cholesterol: DSPC: DMG-PEG2000 = 50:38.5:10:1.5, it was dissolved in anhydrous ethanol and mixed to form a lipid mixture (oil phase). The flow rate of the aqueous phase and the oil phase was controlled (3:1) by T mixing, with a total flow rate of 12-50ml / min, to mix the mRNA and the lipid mixture to obtain LNP-encapsulated mRNA. The encapsulated LNP was diluted with buffer (pH5.0-5.5), then concentrated by ultrafiltration, and the diluent was replaced. Finally, the LNP was concentrated to 200μg / mL-600μg / mL of mRNA, and the pH of the LNP was adjusted to about 7-8. Finally, Quant-iT TM RiboGreen TM The total and free mRNA content in LNPs was determined using an RNA Assay Kit (Invirtogen by Thermo Fisher Scientific, Cat. No. R11490) and 10% Triton X-100 solution or 10% OTG solution as a demulsifier. The LNP encapsulation efficiency was also calculated. The final LNP product was diluted with diluent, 1 ml of which was added to a particle size pool. The LNPs were then placed on a Malvern ZetaSizer instrument for particle size measurement. The results are shown in Table 1.

[0627] Table 1: Characterization data of LNPs of example compounds

[0628] Test Example 2 Toxicity Test

[0629] Nanoparticle samples containing different lipids were administered intravenously to rats (SD rats, Zhejiang Weitong Lihua Laboratory Animal Technology Co., Ltd., 3 rats per group, weight: female: 220-300 g, male: 260-340 g) at a dose of 3 mg / kg. The expression of various clinical markers was assessed 24 hours after administration and compared with that induced by an SM102 LNP formulation (i.e., an LNP formulation made with the known SM102 lipid, prepared according to the method of Experimental Example 1 and in the same proportions) and phosphate-buffered saline (PBS).

[0630] Table 2

[0631] The results are shown in Table 2. Compared with the SM102 group, the values ​​of aspartate aminotransferase and alanine aminotransferase in the compound group of the present invention were significantly decreased, indicating that the toxicity of the compound of the present invention was further reduced, indicating that it has higher biosafety.

[0632] Experimental Example 3 Delivery and Expression Effects of the Lipid Nanoparticle Composition of the Present Invention

[0633] Five balb / c mice (Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd., female, 6-8 weeks old, 18-20g) were taken as a group, and the tail of each balb / c mouse was marked with tail numbers 1# to 5# with a black marker; each group of five mice was sequentially injected intramuscularly (IM) with 5 μg of the lipid nanoparticle composition. The lipid nanoparticle composition of the present invention was prepared according to Experimental Example 1, wherein Luciferase mRNA was encapsulated. A parallel MC3LNP group was set as a reference (i.e., an LNP preparation made from the known MC3 lipid, which was prepared according to the method and proportions of Experimental Example 1).

[0634] Fluorescence detection was performed on each group of mice 24 hours after intramuscular administration of samples (each group was given fluorescein sodium salt YEASEN, LOT: D5330150, IP, 150 mg / kg 10 minutes in advance). The mice were anesthetized and placed in the small animal in vivo optical imaging system in the order of tail tags 1# to 5#. LT Series III, detecting whole-body fluorescence to evaluate the delivery and expression of formulated luciferase mRNA.

[0635] The delivery and expression effects of the compounds of the present invention LNP are shown in Figure 1, with the expression level of MC3 as a reference. The data show that the delivery and expression effects of the compounds of the present invention are excellent, achieving delivery and expression effects comparable to or even better than MC3. In particular, the delivery and expression effects of compound 2, compound 2A, compound 5, compound 5A, compound 5B, compound 8, compound 13, compound 14, and compound 20A are 3-4 times that of MC3. Judging from the results of compound 2, 2A, compound 5, compound 5A, and compound 5B, the difference in configuration does not significantly affect the delivery activity of the ionizable lipid of the present invention.

[0636] Test Example 4 Extrahepatic delivery effect test of the lipid compound of the present invention

[0637] Five balb / c mice (Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd., female, 6-8 weeks old, 18-20g) were taken as a group, and the tail of each balb / c mouse was marked with tail numbers 1# to 5# with a black marker; each group of five mice was sequentially intravenously injected with 20μg of a lipid nanoparticle composition. The lipid nanoparticle composition of the present invention was prepared according to Experimental Example 1, wherein Luciferase mRNA was encapsulated. A phosphate-buffered saline (PBS) group was set up in parallel as a blank control, and an MC3 group was used as a reference (prepared according to the method and proportions of Experimental Example 1).

[0638] Fluorescence detection was performed on mice in each group 24 hours after intravenous administration of samples (fluorescein sodium salt (YEASEN, LOT: D5330150 IP, 150 mg / kg) was administered to each group 10 minutes in advance). The mice were anesthetized and placed in the small animal in vivo optical imaging system in the order of tail tags 1# to 5#. LT Series III, detecting whole-body fluorescence to evaluate the delivery and expression of formulated luciferase mRNA.

[0639] After the test, the mice were killed by dislocating the neck and then dissected to remove the liver, spleen, stomach, and intestines. The organs were arranged in the corresponding positions from 1# to 5# for organ fluorescence detection.

[0640] The results are shown in Figures 2A-2D. The groups of compound 2A, compound 5A, and compound 13 of the present invention achieved significant extrahepatic delivery effects, and the extrahepatic delivery effects were significantly better than those of the MC3 and compound 20A groups, indicating that the compounds of the present invention have reduced liver accumulation toxicity and improved extrahepatic delivery properties.

[0641] Test Example 5 Toxicity Test

[0642] The day before administration, the animals were grouped according to body weight (five per group) (Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd., male, weight: 170-220 g). The animals were weighed before administration and administered a single intravenous dose of a lipid nanoparticle composition based on compound 2A, compound 5A, compound 13, and compound 20A of the present invention (prepared according to Test Example 1) according to body weight. The lipid nanoparticle composition encapsulates Luciferase mRNA. SM102 LNP, MC3 LNP (all prepared according to the method and ratio of Test Example 1) and phosphate buffered saline (PBS) were set in parallel as control groups.

[0643] The administration volume was 10 mL / kg and the administration dose was 3 mg / kg.

[0644] Testing frequency: Collect non-anticoagulated blood before and 24 hours after administration. The blood collection method is as follows:

[0645] Non-anticoagulated blood was collected (the subjects were fasted but not watered the night before sampling, and were fed after sampling). The non-anticoagulated whole blood was allowed to stand at room temperature for 30 min, centrifuged at 5000 rpm for 5 min, and serum (200 μl) was collected. ALT (alanine aminotransferase) and AST (aspartate aminotransferase) in the serum were detected using an automatic biochemical detector (fully automatic biochemical detector 7060 Hitachi).

[0646] During the experiment, 4 rats in the MC3 group died, and all 5 rats in the compound 20A group died.

[0647] The results are shown in Figures 3A-3B. Compared with the MC3 group and the SM102 group, the aspartate aminotransferase and alanine aminotransferase values ​​of the compound 2A, compound 5A, and compound 13 groups of the present invention are lower than those of the ionizable lipid MC3 and SM102 groups used in LNP in commercial products, indicating that the compounds of the present invention have lower hepatotoxicity and higher biosafety.

[0648] Although the embodiments of the present application are described above, the present application is not limited to the above-mentioned specific embodiments and application fields. The above-mentioned specific embodiments are merely illustrative and instructive, and not restrictive. A person of ordinary skill in the art, under the guidance of this specification and without departing from the scope of protection of the claims of this application, can also make many forms, all of which fall within the scope of protection of this application.

Claims

1. A compound of formula (I), or a salt thereof or a stereoisomer thereof, in, R1 is Among them, R 1a and R 1b R2 and R3 are independently selected from H or C1-C6 alkyl, and R2 and R3 are independently selected from H or C1-C6 alkyl, or R1 and R2 together with the carbon atoms to which they are attached form a substituted or unsubstituted 5-7 membered nitrogen-containing heterocyclic ring, and R3 is selected from H or C1-C6 alkyl, or R1 and R3 together with the carbon atom to which they are attached form ring A, wherein ring A is a substituted or unsubstituted 5-7 membered carbocyclic ring or heterocyclic ring, and R2 is selected from H or C1-C6 alkyl; R4, R5 and R6 are independently selected from C1-C14 alkyl; X and Y are independently selected from O or S; X1 and X2 are independently selected from C=O or O, and Y1 and Y2 are independently selected from C=O or O, provided that X1 and Y1, X2 and Y2 are not C=O or O at the same time; m and n are independently selected from 0, 1 or 2, provided that m and n are not 0 at the same time; o and p are independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; q is selected from 0, 1, 2, 3, 4, 5 or 6.

2. The compound or salt thereof or stereoisomer thereof according to claim 1, wherein the compound of formula (I) is formula (IA), in, q is selected from 1, 2, 3 or 4.

3. A compound or salt thereof or a stereoisomer thereof according to any one of the preceding claims, wherein: R4 is a C9, C10, C11 or C12 straight chain alkyl; and R5 and R6 are each independently selected from a C6, C7, C8 or C9 straight chain alkyl.

4. A compound or salt thereof or a stereoisomer thereof according to any one of the preceding claims, wherein: o is 5 or 6.

5. A compound or salt thereof or a stereoisomer thereof according to any one of the preceding claims, wherein: p is 7 or 8.

6. A compound or salt thereof or a stereoisomer thereof according to any one of the preceding claims, wherein: X and Y are both O.

7. A compound or salt thereof or a stereoisomer thereof according to any one of the preceding claims, wherein: n is 1 and m is 0; or n is 1 and m is 1; or n is 0 and m is 1.

8. A compound according to any one of the preceding claims, or a salt thereof, or a stereoisomer thereof, wherein the compound of formula (I) is selected from the following structural formula 9. A compound according to any one of the preceding claims, or a salt thereof, or a stereoisomer thereof, wherein the compound of formula (I) is selected from the following structural formula 10. A compound according to any one of the preceding claims, or a salt thereof, or a stereoisomer thereof, wherein the compound of formula (I) is selected from the following structural formulas:

11. A compound or salt thereof or a stereoisomer thereof according to any one of the preceding claims, wherein: C1-C6 alkyl is independently selected from -CH3, -CH2CH3 or -CH(CH3)2.

12. A compound according to any one of the preceding claims, or a salt thereof, or a stereoisomer thereof, wherein: R 1a and R 1b are independently selected from -CH3; R2 and R3 are independently selected from H; R4 is a C10, C11 or C12 straight chain alkyl; R5 and R6 are the same and are selected from C6, C7 and C8 straight chain alkyl; X and Y are independently selected from O; X1 and X2 are independently selected from C=O or O, and Y1 and Y2 are independently selected from C=O or O, provided that X1 and Y1 are not C=O or O at the same time, and X2 and Y2 are not C=O or O at the same time; m is 0, and n is 1; o is 5 or 6; p is 7 or 8, for example, p is 7; q is 2, 3 or 4, for example q is 2 or 3, for example q is 2.

13. The compound or salt thereof or stereoisomer thereof according to any one of claims 1 to 12, wherein: X1 and X2 are both C═O, and Y1 and Y2 are both O.

14. The compound or salt thereof or stereoisomer thereof according to any one of claims 1 to 12, wherein: X1 is O, Y1 is C=O, and X2 is C=O, Y2 is O.

15. The compound or salt thereof or stereoisomer thereof according to any one of claims 1 to 12, wherein: X1 is C=O, Y1 is O, and X2 is O and Y2 is C=O; or, X1 and X2 are both O, and Y1 and Y2 are both C=O.

16. A compound or salt or stereoisomer thereof according to any one of the preceding claims, wherein: R4 is a C10-C11 straight chain alkyl group.

17. A compound according to any one of the preceding claims, or a salt thereof, or a stereoisomer thereof, wherein: R5 and R6 are both C8 straight chain alkyl.

18. A compound according to any one of the preceding claims, or a salt thereof, or a stereoisomer thereof, wherein: o is 5, R4 is a C11 straight chain alkyl, p is 7, and R5 and R6 are both C8 straight chain alkyl or o is 6, R4 is a C10 straight chain alkyl, p is 7, and R5 and R6 are both C8 straight chain alkyl.

19. The compound or salt thereof or stereoisomer thereof according to claim 1, wherein: The compound is selected from 20. The compound or salt thereof or stereoisomer thereof according to claim 1, wherein: The compound is selected from:

21. A method for preparing the compound according to any one of claims 1 to 20, wherein: Compound (IA) is obtained from compound J as a starting material. wherein Z1 is selected from hydroxyl, Z2 and Z3 are independently selected from hydroxyl or thiol, and Z4 is selected from OMs; and X, Y, X1, X2, Y1, Y2, R 1a , R 1b , R2, R3, R4, R5, R6, m, n, o, p and q are as defined in any one of claims 1 to 20; Wherein, the compound J and the compound K react in a benzene solution of 4-methylbenzenesulfonate pyridinium to generate the compound L, and the benzene solvent used in the benzene solution is preferably toluene; The compound L is reacted in a halogenated alkane solution of (CH3SO2)2O to generate a compound M, wherein the halogenated alkane is preferably DCM, dichloroethane or chloroform; The compound M reacts in a polar aprotic solvent to generate a compound IA, wherein the polar aprotic solvent is preferably is THF.

22. The preparation method according to claim 21, wherein Compound J is obtained from compound H and compound C as starting materials, wherein X is selected from halogen; and X1, X2, R4, R5, R6, o and p are as defined in any one of claims 1 to 20; Wherein, the compound H and the compound C react in the presence of carbonate, NBu4I and a polar aprotic solvent to generate compound I, the carbonate is preferably Cs2CO3 or K2CO3; the polar aprotic solvent is preferably DMF or DMA; The compound I reacts at a pH of 1-5 to generate compound J. Preferably, the pH is adjusted by a hydrochloric acid solution. The reaction solvent is a halogenated alkane, preferably DCM, dichloroethane or chloroform.

23. The preparation method according to claim 22, wherein: Compound F and compound G react to obtain compound H, wherein X is selected from halogen; X1, Y1, R4 and o are as defined in any one of claims 1 to 20; Wherein, the compound F and compound G react in the presence of carbonate, NBu4I and a polar aprotic solvent to generate compound H, wherein the carbonate is preferably Cs2CO3 or K2CO3; and the polar aprotic solvent is preferably DMF or DMA.

24. A nanoparticle composition comprising a lipid component, wherein the lipid component comprises the compound or salt thereof or a stereoisomer thereof according to any one of claims 1 to 20; preferably, the nanoparticle composition is a lipid nanoparticle (LNP).

25. The nanoparticle composition of claim 24, wherein the lipid component further comprises phospholipids, structural lipids and / or PEG lipids; The phospholipids are preferably selected from one or more of the following compounds: Dilauroyl phosphatidylcholine (DLPC), Dimyristoylphosphatidylcholine (DMPC), Dioleoylphosphatidylcholine (DOPC), Dipalmitoylphosphatidylcholine (DPPC), Distearoylphosphatidylcholine (DSPC), Dioleoylphosphatidylcholine (DUPC), Palmitoyloleoylphosphatidylcholine (POPC), 1,2-Di-O-octadecyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesteryl dimethylsuccinate-sn-glycero-3-phosphocholine (OChemsPC), l-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-Divinyl-sn-glycero-3-phosphocholine, 1,2-Diaryl acyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine (DOPE), 1,2-Dihydroxytin-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-Divinyl alcohol-sn-glycero-3-phosphoethanolamine, 1,2-Divinyl-sn-glycero-3-phosphoethanolamine, 1,2-Diaryl-sn-glycero-3-phosphoethanolamine, 1,2-dithiohexaenoic acid-sn-glycero-3-phosphoethanolamine, 1,2-diol-sn-glycero-3-phospho-(1-glycero) sodium salt (DOPG) or sphingomyelin, For example, the phospholipid is DOPE or DSPC; The structural lipid is preferably selected from one or more of cholesterol, coprostanol, sitosterol, ergosterol, and stigmasterol; for example, the structural lipid is cholesterol; and / or The PEG lipid is preferably selected from one or more of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol or PEG-modified dialkylglycerol.

26. The nanoparticle composition of any one of claims 24-25, wherein the lipid component further comprises a cationic and / or ionizable lipid.

27. The nanoparticle composition according to any one of claims 24 to 26, further comprising a therapeutic and / or prophylactic agent selected from a vaccine or a compound capable of eliciting an immune response, and / or a nucleic acid, Preferably, the nucleic acid is RNA, and the RNA is selected from one or more of siRNA, aiRNA, miRNA, dsRNA, shRNA or mRNA.

28. The nanoparticle composition of any one of claims 24-27, wherein: The encapsulation rate of the therapeutic agent and / or preventive agent is ≥50%; or ≥80%; or ≥90%; and / or The average particle size of the nanoparticle composition is 50nm-110nm; and / or The dispersibility index of the nanoparticle composition is 0.04-0.

20.

29. Use of the compound or salt or stereoisomer thereof according to any one of claims 1 to 20 in preparing a lipid nanoparticle composition.

30. A pharmaceutical composition comprising the nanoparticle composition of any one of claims 24-28 and a pharmaceutically acceptable excipient.

31. A method for delivering a therapeutic and / or prophylactic agent to a mammalian cell, the method comprising administering to a subject the nanoparticle composition of any one of claims 24-28 or the pharmaceutical composition of claim 30, the administration comprising contacting a cell with the nanoparticle composition or the pharmaceutical composition to deliver the therapeutic and / or prophylactic agent to the cell; e.g., the mammalian cell is in a mammal; e.g., the mammal is a human; e.g., the nanoparticle composition or the pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

32. A method for producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the nanoparticle composition of any one of claims 24-28 or the pharmaceutical composition of claim 30 to deliver a therapeutic and / or prophylactic agent to the cell, wherein the therapeutic and / or prophylactic agent is mRNA encoding the polypeptide of interest, whereby the mRNA can be translated in the cell to produce the polypeptide of interest; e.g., the mammalian cell is in a mammal; e.g., the mammal is a human; e.g., the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation.

33. A method for treating or preventing a disease or condition in a mammal, such as a human, comprising administering to the mammal a therapeutically or prophylactically effective amount of the nanoparticle composition of any one of claims 24-28 or the pharmaceutical composition of claim 30; for example, the disease or condition is characterized by dysfunction or abnormality of protein or polypeptide activity; for example, the disease or condition is selected from infectious diseases, cancer and proliferative diseases, genetic diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular diseases, renal vascular diseases or metabolic diseases; for example, the nanoparticle composition or pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally or by inhalation.

34. A method for specifically delivering a therapeutic and / or prophylactic agent to an organ of a mammal, the method comprising administering to the mammal the nanoparticle composition of any one of claims 24-28 or the pharmaceutical composition of claim 30, wherein the administration comprises contacting the mammalian organ with the nanoparticle composition or the pharmaceutical composition, thereby delivering the therapeutic and / or prophylactic agent to the organ; for example, the mammal is a human; for example, the nanoparticle composition or the pharmaceutical composition is administered intravenously, intramuscularly, intradermally, subcutaneously, intranasally, or by inhalation; for example, the mammal is pretreated 24 hours or less prior to the contacting or administering step; for example, the mammal is pretreated about one hour prior to the contacting or administering step.